No retraction, correction or concern found when last checked on Oct 20, 2026.

Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions

Jun Ma, Yanan Li, Xiangyu Yang and 8 more

Signal Transduction and Targeted Therapy · 2023 · Review · CC BY

Abstract

Hypertension is a global public health issue and the leading cause of premature death in humans. Despite more than a century of research, hypertension remains difficult to cure due to its complex mechanisms involving multiple interactive factors and our limited understanding of it. Hypertension is a condition that is named after its clinical features. Vascular function is a factor that affects blood pressure directly, and it is a main strategy for clinically controlling BP to regulate constriction/relaxation function of blood vessels. Vascular elasticity, caliber, and reactivity are all characteristic indicators reflecting vascular function. Blood vessels are composed of three distinct layers, out of which the endothelial cells in intima and the smooth muscle cells in media are the main performers of vascular function. The alterations in signaling pathways in these cells are the key molecular mechanisms underlying vascular dysfunction and hypertension development. In this manuscript, we will comprehensively review the signaling pathways involved in vascular function regulation and hypertension progression, including calcium pathway, NO-NOsGC-cGMP pathway, various vascular remodeling pathways and some important upstream pathways such as renin-angiotensin-aldosterone system, oxidative stress-related signaling pathway, immunity/inflammation pathway, etc. Meanwhile, we will also summarize the treatment methods of hypertension that targets vascular function regulation and discuss the possibility of these signaling pathways being applied to clinical work.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Hypertension represents a significant risk factor for cardiovascular and cerebrovascular diseases (CVDs) and remains the primary cause of premature mortality on a global scale. The estimated number of people aged 30–79-year-old with hypertension doubled from 648 million in 1990 to 1.27 billion in 2019. The prevention and control of hypertension represent a crucial global public health strategy in the effort to reduce premature mortality from CVDs.

2Blood pressure (BP) is defined as the lateral pressure exerted on the walls of blood vessels per unit area during the flow of blood. Hypertension is characterized by an increase in systolic BP and/or diastolic BP. There are two primary factors that directly affect BP: the volume of intravascular fluid and the capacity for vasodilation. The amount of fluid in the blood vessels is mainly related to the everyday intake and output volume. Vasodilatation is the basic function of blood vessels. The capacity for vasodilation is influenced by vascular elasticity, caliber, and reactivity. Poorer the vasodilatation capacity, higher the BP. The disturbance of vascular contraction and/or relaxation function exerts a great influence on the onset and progression of hypertension. As vasodilatation capacity plays a crucial role in regulating BP, it has garnered significant attention in the field of vascular biology research.

3Changes in signaling pathways in vascular endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are key molecular mechanisms which trigger vascular dysfunction and promote the development of hypertension. Here, we reviewed all key signaling pathways in vascular function and hypertension, as well as their treatment application value in clinical settings.

Vascular structure and functions of each layer

4Blood vessels are composed of three distinct layers, including intima, media, and adventitia (Fig. 1). The intima is mainly composed of ECs, which organize themselves into a continuous monolayer, allowing blood perfusion. On their surface, ECs form a surrounding extracellular matrix (ECM) known as the glycocalyx, which extends beyond the cell surface into the vascular lumen. This structure plays a crucial role in providing a barrier function for ECs, preventing the transmural migration of leukocytes and platelet adhesion., Intima is the “sensor” of vessels, as it can sense various stimuli (such as fluid shear force, cytokines, etc.) in the blood and actively control the degree of vascular relaxation and contraction. This active regulation is mainly achieved through the secretion of various mediators from ECs. ECs serve not only as a barrier-forming cell population, acting as a responsive interface, but also actively regulate their microenvironment, serving as gatekeepers of organ development, homeostasis, and tissue regeneration. ECs dysfunction has been regarded as a pivotal mechanism in early pathogenesis of hypertension. Generalized definition of ECs function or endothelial function involves barrier, secretion, sensation, etc., while in studies with respect to vascular contraction, endothelial function commonly refers specifically to ECs sensing the stimuli from blood and triggering vascular contraction.

5Under the ECs is a layer of basement membrane (mainly consisting of type IV collagen and laminins 411) that supports ECs, and under the basement membrane is the middle layer. The medial layer of arteries serves as the load-bearing unit and regulates arterial vascular tone, providing the necessary structural stability for the regulation of blood flow and delivery of oxygen to tissues. Generally, the farther from the heart, the thinner the middle layer in the arteries. Media layers are absent in the capillaries, which allows adequate exchange of gases and fluids through capillaries., In large (elastic) arteries, elastic fibers interweave with VSMCs, and are surrounded by other ECM. VSMCs are the main function performer in regulating vasoconstriction and dilation. Once accepting the external signals, VSMCs can transmit the signals by intracellular signaling pathways, thus activating the Actin in VSMCs and triggering cells contraction. Healthy ECM is responsible for maintaining the structure of the middle layer of blood vessels and directly affecting the function and status of VSMCs. Compared with the intima and media, the composition of the adventitia is more complex. The adventitia contains fibroblasts incorporated into a loose collagen extracellular matrix (ECM) enriched in hyaluronic acid. Lymphocytes, nerves, progenitors, adipocytes, and immune cells are also present in the adventitia.– Functionally, the adventitia can sense and direct responses to a wide array of stimuli via reciprocal communication among adventitial cells, as well as with cells from neighboring tissues, acting as a biological processing center for the retrieval, integration, and storage.

Classical signaling pathways in vascular function and hypertension

6Abnormal vascular structure is an important cause of hypertension and cardiovascular events.– An increase in vascular resistance, largely caused by a reduction in vascular diameter,, is a key pathophysiological mechanism contributing to the development of hypertension. The signaling pathways underlying vascular function and hypertension are complex. There are three classical ways to regulate vascular function and BP levels, including calcium signaling pathway, the NO (nitric oxide)-NOsGC (nitric oxide-sensitive guanylate cyclase)-cGMP pathway, and vascular remodeling. Among them, calcium and NO-NOsGC-cGMP signaling pathway are reversible, and vascular remodeling is considered as a pathological change that is difficult to reverse.

Calcium signaling pathway

7The primary mechanisms regulating the contractile state of VSMCs are changes in cytosolic calcium concentration ([Ca2+]c). When vasoconstrictor stimuli are present, intracellular stores and/or the extracellular space mobilize Ca2+ to increase [Ca2+]c in VSMCs (Fig. 2). The increased [Ca2+]c will bind to calmodulin (CaM) and form a complex which can activate myosin light-chain (MLC) kinase (MLCK). Then MLCK will phosphorylate MLC to promote contraction. Conversely, myosin light chain phosphatase (MLCP) can dephosphorylate phosphorylated MLC, triggering vasodilation.– One of the important procedures in calcium signaling pathways is the influx of extracellular calcium through voltage-gated Ca2+ channels. There exist two main types of Ca2+ channels in VSMCs, including the high voltage-activated (HVA) L-type and low voltage-activated (LVA) T-type channels. The primary function of L-type channels is to regulate Ca2+ entry for contraction. Nevertheless, it is generally accepted that T-type Ca2+ channels (LTCCs) do not play a significant role in arterial vasoconstriction, except possibly in the renal microcirculation. Many factors, including humoral or neural stimuli, can affect the function (open or close) of LTCCs. And functional regulation of Ca2+ channel relies on phosphorylation processes. Except calcium influx, Ca2+ release from the internal store (sarcoplasmic reticulum; SR) through the IP3 receptor (IP3R) and the ryanodine receptor (RyR) is also an important way to modulate cellular contraction.,,

8In addition to the amount of calcium ions in the cytoplasm, contraction is also regulated by calcium-sensitization mechanisms, such as the RhoA-Rho kinase pathway, and the PLC (phospholipase C)–DAG (Diacylglycerol)–PKC (protein kinase C) pathway., RhoA is a small GTP-binding protein acting as molecular switcher in signaling pathway, and Rho-kinases (Rho-kinase α/ROKα/ROCK2 and Rho-kinase β/ROKβ/ROCK1) are downstream proteins of RhoA.– Rho-kinases contribute to the contraction of VSMCs via Phosphorylation of MLC.– Moreover, enhanced RhoA/Rho-kinase (Rho-associated kinase) signaling in VSMCs is considered to be involved in the elevated peripheral vascular resistance observed in clinical hypertension.,, PLC is a phosphodiesterase released through the action of specific phospholipases, and is a downstream product of GPCRs (G-protein-coupled receptors). PIP2 (Phosphatidylinositol-4,5-bisphosphate) is a minor phospholipid, which is generated by the hydrolysis of a minor phospholipid in the plasma membrane in response to agonist stimulation. When acted upon by a phosphoinositide-specific PLC (PI-PLC) enzyme, PIP2 can generate two intracellular second messengers: (1) IP3 (inositol trisphosphate), which subsequently mobilizes Ca2+ from ER stores via IP3 receptor; and (2) DGA, which activates PKC. Activation of PKC can lead to constriction of aorta and BP increasement, via downstream targets of PKC, such as MLCK and CPI-17 (C-kinase potentiated protein phosphatase 1 inhibitor, molecular mass 17 kDa), both of which enhance constriction., Notably, CPI-17 is a smooth-muscle-specific inhibitor of MLCP, which can bind to its catalytic subunit, impending its phosphatase activity and enabling the persistence of contraction. Both PKC and Rho/Rho kinase can induce the enhancement of contractile force via CPI-17.,

NO-NOsGC-cGMP pathway

9The NO-NOsGC-cGMP pathway is closely linked to the contractile function of VSMCs, and its activation precedes the development of hypertension– (Fig. 3). The generation of NO in vascular ECs is the beginning of NO-NOsGC-cGMP pathway. NO production can be stimulated by many chemical factors including L-arginine, nitrate, nitrite, catecholamines,, bradykinin, serotonin, and physical factors such as fluid shear stress. And NO can be inactivated by angiotensin II. There are two pathways by which NO is produced in ECs, including endothelial NOS (eNOS) pathway and eNOS-independent pathway (such as nitrate, nitrite). NO produced from L-arginine by eNOS pathway is the primary source of blood NO., And eNOS knockout has been proven to lead to vascular dysfunction and hypertension. To be mentioned, a recent study revealed that eNOS did not only contribute to BP regulation in ECs, but also in RBCs. Both the EC and RBC eNOS KOs were significantly hypertensive, and the apply of the NO synthase inhibitor further upregulated BP in these mice. On the one hand, it indicated the diversity of NO sources in blood vessels. On the other hand, it also suggested that the changes in the quantity of RBCs might affect BP regulation.

10NO synthesized in ECs or RBCs can diffuse into VSMCs, and this procedure is regulated by transformation of Fe2+ hemoglobin (Hb) α and oxidized Fe3+ Hb α. Endothelial Hb α haem iron in the Fe3+ state enables NO signaling, while this signaling is terminated when Hb α is converted to the Fe2+ state by endothelial CYB5R3 (cytochrome b5 reductase 3). In VSMCs, NO activates NOsGC, which subsequently generates the second messenger cGMP., cGMP exerts its cellular functions via cGMP-modulated cation channels (cyclic nucleotide-gated [CNG]) and cGMP-dependent protein kinases (cGKs). One of the cGKs substrate, cGKIα, can bind to and then phosphorylate the myosin-binding subunit of MLC phosphatase, which is crucial for the localization of cGKI near the enzyme it regulates.– Besides, transfection of cGKIα could rescue defective Ca2+ regulation in cGKI-deficient VSMCs according to studies, and cGKI activated myosin-bound phosphatase by inhibition of RhoA/Rho-kinase pathway. All the evidence demonstrated that, cGKIα was also able to relax VSMCs by decreasing the cytosolic Ca2+ level and calcium-sensitization, suggesting NOsGC-cGMP pathway had a crosstalk with calcium signaling.

Vascular remodeling

11Vascular remodeling presents as vascular lumen narrowing, vascular wall thickening, and elasticity loss. It can be put on a par with clinically structural arterial stiffness, which is reflected as pulse wave velocity (PWV) increasement. ECM changes in vessels are pathological conditions which lead to vascular remodeling and hypertension (Fig. 4). No method has been found to reverse the altered ECM to a healthy state currently, and researches in this direction may be the key to breakthroughs in restoring vascular function and curing hypertension. The changes of ECM mainly occur in the media, which may be related to the different SMC phenotypes and different secretory factors from SMCs. The changes of ECM include deposition of excessive collagen and glycation end-products deposition (AGEs), elastic fibers degradation, calcification etc.,–

MMPs

12Matrix metalloproteinases (MMPs) are a group of endopeptidases that depend on zinc and are responsible for breaking down proteins in the ECM. Activated MMPs can deposit collagen, degrade elastin, and then lead to BP increasement.,– At least 28 different types of MMPs are expressed in human tissue. Many types of MMPs are involved in arterial remodeling and BP regulation, including MMP-1,– MMP-2,– MMP-3,, MMP-9,,, etc. The roles played by MMPs in regulating ECM are not entirely consistent. According to their functions, MMPs can be classified into different types, including collagenases, gelatinases, matrilysins, stromelysins etc.– Collagenases, like MMP-1 (interstitial collagenase), can degrade collagen and cleave proMMP-9 into its active form. Gelatinases involve MMP-2 (gelatinase A), MMP-9 (gelatinase B), contributors to degradation of gelatin etc. In addition to the basic functions mentioned above, some MMPs can also function in other ways. For instance, the activation of MMP-2 can lead to calcification, and collagen accumulation in the vascular wall. MMP-9 can cause vascular fibrolysis and enhanced collagen affinity., In addition to acting on vascular remodeling to affect structure, MMPs may also affect BP through other mechanisms. Activation of MMP-2 contributes to an increase in BP by both elevating the levels of big endothelin-1 and reducing the levels of adventitial calcitonin gene-related peptide and endothelial nitric oxide synthase.– MMP-1/-9 decreases the density of β (2) adrenergic receptor in arterioles, leading to an increase in arteriolar tone, which also contributes to an elevation in BP.,

13The activity of MMPs is regulated at three levels: proenzyme activation, activity inhibition (tissue inhibitors of MMPs, TIMPs), and gene transcription., During vascular remodeling, the activation of intracellular MMPs is associated with multiple stimulators, commonly including pro-inflammatory signaling molecules (cytokines, interleukins, tumor necrosis factors), growth factors, vasoactive agents (Ang II, ET-1, aldosterone) and their receptors. Signaling pathways involved in regulating MMPs transcription mainly include mitogen-activated protein kinase (MAPK),,, reactive oxygen species (ROS), adenosine 5’-monophosphate-activated protein kinase (AMPK),, extracellular-signal-regulated kinase (ERK), JUN N-terminal kinase (JNK) etc., which can either enhance or repress the expression of MMPs. In addition to these general pathways, different types of MMPs may have specific signaling pathways. For example, MMP10 gene transcription is inhibited by HDAC7 (Histone Deacetylase 7) binding to MEF2 (myocyte enhancer factor 2), resulting in endothelial cell–cell adhesion and impaired vascular integrity.

AGEs

14Reactive byproducts resulting from nonenzymatic glucose–protein condensation reactions, as well as lipids and nucleic acids exposed to reducing sugars, form a diverse group of irreversible adducts known as “Advanced Glycation Endproducts” (AGEs). AGEs can be formed by glycation of proteins either within cells or in extracellular spaces. This protein glycation consists of a series of complex sequential reactions, known collectively as the Maillard reaction. Multiple cardiovascular risk factors can result in increase in serum and tissue AGEs, such as diabetes, hyperlipidemia, smoking, etc. According to the sources, AGEs can be classified into endogenous AGEs (intra- and extracellular) and exogenous AGEs taken in from certain foods. The formation of methylglyoxal (MGO) is a major precursor of endogenous AGEs, occurs spontaneously during glycolysis from the triose phosphate isomers glyceraldehyde-3 phosphate and dihydroxyacetone phosphate.,, Other crucial AGEs compounds include glyoxal (GO), 3-deoxyglucosone (3DG), Nε-carboxymethyl-lysine (CML), Nε-carboxyethyl-lysine (CEL), pentosidine, pyrraline, and glucosepane. Food is the primary sources of exogenous AGEs in human. Generally, animal fat foods contain more AGEs than plant foods. And cooking at high temperature can increase AGEs in foods. Moreover, studies have confirmed that controlling dietary habits is an effective way to reduce AGEs in human body.–

15AGEs contribute a lot to vascular remodeling and hypertension. Accumulation of AGEs in ECM leads to the formation of cross-links, which can entrap other local macromolecules., There are three known receptors for AGEs: full-length AGE receptor (RAGE), N-truncated RAGE, and soluble RAGE (sRAGE). sRAGE has two isoforms, including cleaved RAGE (cRAGE) and endogenous secretory RAGE (esRAGE). Full-length RAGEs and N-truncated RAGEs are multiligand cell bound receptors, while sRAGEs circulate in the blood. AGEs and their receptors are closely associated with vascular function and hypertension. Plasma levels of AGEs are significantly higher in individuals with hypertension compared to those without hypertension and are associated with aortic stiffness independent of age and BP. Skin AGEs, an important indicator of the current level of accumulated AGEs, is associated with vascular stiffening independent of age and other cardiometabolic risk factors, not only in individuals with diabetes but also in those in normoglycemic and prediabetic conditions. Besides, studies reported an inverse correlation between sRAGE and BP,, and sRAGE showed its potential in predicting cardiovascular events and/or mortality in diabetics.

16Mechanistically, the properties of collagen can be altered through AGEs–RAGE intermolecular covalent bonds or cross-links. Cross-links between AGEs and collagen or elastin increase the extracellular matrix area.– On the other hands, cross-linking renders collagen insoluble to hydrolytic enzymes, and collagen linked with AGEs is less susceptible to hydrolytic turnover, making it stiffer., And these factors combined result in vascular remodeling and dysfunction. In intracellular pathway, studies showed interaction of AGEs with full-length RAGE via PI3K, MAPK, ERK1, and ERK2 activates NF-κB (nuclear factor κB), stimulating inflammation and various cytokines secreting., In addition to these cascades leading to inflammation, RAGE activation can increase ROS via NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, and lead to oxidative stress and dysfunction in cells.– Notably, RAGE is not only activated by AGEs but also stimulated by other factors including S100 proteins, HMGB-1 (High mobility box group-1), Mac-1 integrin, and ox-LDL (oxidized low-density lipoprotein), thus resulting in vascular dysfunction.,,– On the contrary, sRAGE can fuction as a decoy receptor for RAGE ligands, effectively binding to them and exerting protective effects against the harmful consequences of the AGE-RAGE interaction on vascular function.

Calcification

17Vascular calcification refers to the process of calcium deposition in the extracellular matrix of arterial walls. Vascular calcification involves deposition of mineral in the ECM, VSMCs apoptosis and osteogenic transformations, dysregulated expression of mineralization inhibitors, and microvesicle (MV) release et al.– There is a mutually reinforcing relationship between vascular calcification and hypertension. Hypertension is a calcification-promoting stressor, and vascular calcification can result in hypertension through arterial stiffness.– Arterial stiffness can initiate media calcification through mechano-sensing pathways, which subsequently exacerbate arterial stiffness. Though calcification can occur in intima, media, or adventitia,, it is commonly considered that medial arterial calcification (MAC) contributes the most to the dysfunction of vascular contraction.,– The pathobiological mechanisms of calcification can be classified into 2 categories: the loss of mineralization inhibitors and the induction of osteogenesis.

18MAC is characterized as calcium phosphate depositing in the form of hydroxyapatite in media ECM. Inorganic phosphate is one of the important causes of MAC., Under normal physiological conditions, when the concentrations of calcium and phosphate exceed their solubility limits, the body relies on endogenous calcification inhibitors to prevent the ectopic precipitation of these minerals., Pyrophosphate has been identified as the strongest endogenous inhibitor of mineralization, and it is produced locally by VSMCs.– Pyrophosphate can prevent mineralization through several mechanisms, including direct binding to growing crystals, induction of osteopontin expression, and inhibition of Tnap (an issue-nonspecific alkaline phosphatase) activity. VSMCs are responsible for producing and releasing pyrophosphate into the extracellular space, a process that involves the activation of two proteins: ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase) and ANKH (the transmembrane protein ankylosis protein homolog)., The ENPP1 protein helps break down adenosine triphosphate into AMP (adenosine monophosphate) and pyrophosphate., ANKH protein transports pyrophosphate out of cells to ECM.– Besides, VSMCs are also involved in taking up Fetuin-A from the extracellular space, which is a circulating protein that can bind to calcium or hydroxyapatite directly, to inhibit the growth of hydroxyapatite crystals. And VSMCs can produce several other inhibitory proteins, including matrix-Gla protein, osteopontin, and osteoprotegerin. These proteins can be loaded into extracellular vesicles to prevent vascular mineralization.,, Under pathological conditions, including high extracellular phosphate levels and exposure to uremic toxins, the production of calcification inhibitors by VSMCs can be suppressed. This can further result in the release of exosomal vesicles lacking these inhibitors and promoting vascular mineralization. On the contrary, the load of pro-calcific proteins such as ALPL (tissue-nonspecific alkaline phosphatase) is increased., All these combined can lead to the formation of microcalcifications, which can provide a site for the precipitation of calcium phosphate and the subsequent growth of crystals.–

19Apoptosis and phenotypic switching of VSMCs is also critical to calcification. Apoptotic bodies released by VSMCs can potentially serve as nucleating structures for calcium crystal formation., High extracellular phosphate levels can induce apoptosis and necrosis of VSMCs., Activation of pro-apoptotic signaling pathways in VSMCs can occur due to the involvement of a multitude of upstream signaling cascades in response to phosphate. The downregulation of Gas6 (growth arrest-specific gene 6) and its receptor tyrosine kinase Axl, and activation of apoptosis-related BAD (Bcl2-associated death promoter)/Caspase-3 via PI3K/AKT pathway– or AMPK (AMP-activated protein kinase),– have been thought to be main pathway in apoptosis of VSMCs stimulated by phosphate. Contractile VSMCs converting into osteo-phenotype is also responsible for vascular calcification. Under high extracellular phosphate levels circumstances, VSMCs will undergo a phenotypic switch into osteo-/chondroblast-like cells, and promote vascular mineralization., These phenotypes can express osteogenic transcription factors such as MSX2 (msh homeobox 2), CBFA1 (core-binding factor α-1, also known as RUNX2)– or osterix, as well as chondrogenic transcription factors including SOX9 (SRY-Box 9).– Both CBFA1 and SOX9 play critical roles in vascular osteo-/chondrogenic transdifferentiation and calcification.,, The transcription factors, MSX2 and KLF4, have been proven to be the upstream regulators of CBFA1 and SOX9.– The expression of osteogenic- and chondrogenic-specific proteins in VSMCs, such as osteocalcin, type I collagen, BMP-2 (bone morphogenetic protein-2), or ALPL, is further induced by osteo-/chondrogenic transcription factors., An increase in ALPL activity is a decisive event in vascular calcification, as ALPL is a key regulator of this process.,

Renin-angiotensin-aldosterone system

20Renin-angiotensin-aldosterone system (RAAS) plays a critical role in the regulation of BP. In the RAAS, angiotensinogen and downstream peptides are the main stimulators regulating vasoconstriction (Fig. 5). Angiotensinogen mainly produced by the liver is cleaved by renin into angiotensin I (Ang I). Ang I is cleaved by angiotensin-converting enzyme I (ACE1) to produce angiotensin II (Ang II) or cleaved by angiotensin-converting enzyme 2 (ACE2) to produce Ang (1–9). Ang II exerts various physiological and pathophysiological effects, including vasoconstriction and sodium/water retention, via activation of Ang II type 1 receptor (AT1R) signaling. Moreover, Ang II or Ang (1–9) can be converted to angiotensin 1–7 [Ang (1–7)], and Ang (1–7) can cause vasodilation and lower BP by binding to Mas receptor (MasR).– Those peptides can have actions on endothelial cells, SMCs, and adventitia cells in vessels. Various peptides activating the receptors on different cells can result in different effects, including apoptosis and endothelial barrier damage for endothelial cells, contraction of SMCs, and fibrosis of atria.– In addition, recent study reported the role of Ang (1–12) in the process of hypertension, the angiotensin family is still under development.

Angiotensin-related receptors

21The signaling pathways of RAAS in cells begin with the activation of various receptors, and the diverse effects of RAAS can be attributed to the activation of different receptors., Angiotensin-related receptors are the main executors of the RAAS system in regulating vasoconstriction and BP. AT1R is a member of the GPCR (G protein-coupled receptor) family and is expressed in various cells including VSMCs, endothelium, cardiomyocytes, etc. Ang II/AT1R play a central role in regulating BP. In VSMCs, AT1R can be stimulated by Ang II and interact with a heterotrimeric G protein including Gq/11 and G12/13. Gq/11 can subsequently activate PLC-IP3-Ca2+-sensitive-MLCK signaling. While G12/13 will active PKC-RhoA/Rho kinase-mediated inhibition of MLCP. In addition, study showed that Ang II/AT1R inhibited the MLCK transcription by blocking the Notch signaling in VSMCs. On the contrary, Ang (1–7)/MasR is a bioactive peptide that can exert diverse effects, many of which are contrary to those induced by Ang II/AT1R.– The Ang 1–7/MasR axis activation acts as a counter-regulator for the effects mediated by Ang II/AT1R, but the exact mechanism remains unclear. A recent study has found that Ang 1–7/MasR axis exerts vasodilation through two mechanisms: a telomerase-dependent manner and direct increase of telomerase activity in human endothelium. Since increased telomerase activity can elevate NO production and endothelial nitric oxide synthase expression, it is supposed that Ang 1–7/MasR-mediated vasodilation may via NO-(NOsGC)-cGMP pathway.

22In addition to Ang II/AT1R and Ang 1–7/MasR, other peptides or receptors are also involved in BP regulation. Upregulation of vascular and plasma ACE2, along with increased plasma Ang 1–9 levels, can exibit a potent antihypertensive effect via RhoA/Rho kinase inhibition, without an increase in Ang 1–7 levels. The AT2R can promote the production of NO and cGMP by two different mechanisms, dependent or independent of the production of bradykinin (BK) via BK B2 receptors.– ANG IV, cleaved from Ang (1–9), can bind to AT4R and cause vasorelaxation via eNOS, too.

Angiotensin-unrelated receptors

23The (pro)renin receptor ((P)RR) is thought to enhance the activity of the tissue renin–angiotensin system by binding to renin or prorenin, and it can activate intracellular tyrosine-phosphorylation-dependent pathways independently of RAAS. However, whether (pro)renin/(P)RR contributes to hypertension in human is controversial. A study showed that in VSMCs, prorenin can induce ERK phosphorylation via (P)RR-mediated activation of tyrosine kinase. This can subsequently lead to a vascular remodeling via MEK, independently of the production of angiotensin II or the activation of its receptors. Another study demonstrated that (P)RR was essential for VSMCs survival and downregulation of vascular inflammation, through maintaining normal function of the vacuolar H(+)-ATPase in Wnt signaling. And the deletion of (P)RR did not affect ambulatory BP levels in murine. To elicit intracellular signaling in vitro, much higher concentrations of (pro)renin are required than those observed in physiological plasma levels. The effects observed in animals overexpressing prorenin could be solely due to the generation of angiotensin, possibly without requiring a receptor. Compared with hypertension, it is now considered that (P)RR and the downstream pathway play more important roles in cell survival. (P)RR knockout, even tissue-specific, is lethal compared to other RAS components knockout, suggesting that (P)RR has an important function independent of (pro)renin., To be mentioned, in clinical studies, the addition of direct renin inhibitors (such as aliskiren) to ARB therapy did not lead to improved renal or cardiovascular outcomes. Conversely, it was associated with a higher incidence of adverse effects compared to ARB therapy alone. According to that, the prospect of targeting (P)RR in the treatment of hypertension is not as good as AT1R. Another angiotensin-unrelated receptor is mineralocorticoid receptor (MR). The mechanism by which MR affects BP involves its binding with aldosterone and subsequent retention of sodium. Mice with MR deficiency in VSMCs exibit decreased vascular myogenic tone, reduced contraction in response to agonists, as well as decreased expression and activity of L-type calcium channels. MR mediates vascular remodeling via several signalings, including RhoA/ROCK, placental growth factor (PLGF), vascular endothelial growth factor type 1 receptor (VEGF1R), and galectin signaling et al.

Redox signaling pathway

24Cellular reduction/oxidation (redox) signaling pathway is responsible for regulating a wide range of cellular functions, including but not limited to homeostasis, differentiation, proliferation, and apoptosis. Cellular oxidative stress occurs when reactive oxygen/nitrogen species (ROS/RNS) is produced. Generally, ROS/RNS substances include hydrogen peroxide (H2O2), hydroxyl radicals (HO), superoxide anion radicals (O2–), nitric oxide (NO), nitrogen dioxide (NO-), peroxynitrite (OONO−), dinitrogen trioxide (N2O3), and nitrous acid (HNO2) radicals. Redox signaling is primarily characterized by an oxidation–reduction reaction or covalent adduct formation that occurs between the sensor signaling protein and second messenger. Multiple transcription factors and enzymes are all redox-sensitive. Redox signaling has been firmly established in vascular function and hypertension (Fig. 6). Activation of redox signaling increases vascular tone by influencing the regulatory role of ECs, and by directly affecting the contractility of VSMCs.– Oxidative modifications affect multiple kinases, such as Src tyrosine kinase, ASK-1, PKG (protein kinase G), and MAPK pathway, by which regulating vascular contraction., As mentioned above, ROS is also an important factor in the activation of MMPs, leading to vascular remodeling and BP increase. Furthermore, the expression and function of various transcription factors, including NF-κB, Nrf-2, AP-1 (activator protein 1), STATs (signal transducers and activators of transcription) etc., are affected by ROS. The activation of these factors can lead to inflammation, total antioxidant status, endothelial dysfunction, and hypertension.,–

25Endogenous ROS/RNS are mainly produced through mitochondrial electron transport chain (ECT),– enzymes NADPH oxidase, and other sources including xanthine oxidase, peroxisomes, endoplasmic reticulum etc. At the same time, there is a scavenging system in redox signaling to maintain ROS/RNS balance in the body.

Mitochondrial electron transport chain

26In physiological conditions, superoxide is generated as a side product of electron transportation during oxidative phosphorylation in SMC mitochondria., Although most superoxides stay in mitochondrial matrix, some can escape to the intermembranous space and cytosol, via anion channels when the superoxides generation is excessive. This is one of the main sources of superoxides contributing to redox signaling activation.

NADPH oxidases

27NADPH oxidases (NOXs) are enzymes that produce superoxides by transporting electrons from NADPH to molecular oxygen. NOXs are well-known as important sources of ROS in blood vessels. NOXs system is composed of NADPH oxidase constituents (such as Nox1, Nox2, Nox4, and Nox5) and cytosolic proteins. Activation of each constituent involves distinct regulatory mechanisms and signaling pathways, which can be attributed, in part, to the variety of cytosolic regulatory subunits, including p47phox, p67phox, Rac, Noxo1, and Noxa1.,, Hypertensive animal models, such as Ang II-induced hypertensive rats, SHR, DOCA-salt hypertensive rats, and two-kidney two-clip renovascular hypertensive rats, have been shown to exhibit increased expression and activity of NADPH oxidase or its cytosolic subunits.– The activation of vascular NADPH oxidases through PKC, Src, or CyPA dependent pathways is an important mechanism by which Ang II functions in the body. Besides, NOX1-derived reactive oxygen species regulate cell-surface AT1R expression by mechanisms like caveolin phosphorylation, which suggests that there is positive feedback between Ang II and NOXs. Other stimulants include PDGF, VEGF, cytokines, wounding,– etc.

Endoplasmic reticulum

28There is growing recognition of the important role that the endoplasmic reticulum (ER) palys in redox pathophysiology, summarized in another review as: (i) ER enzymes, like ER oxidoreductin (Ero1) and its thiol redox partner protein disulfide isomerase (PDI), have a role in the generation of ROS, (ii) ER is responsible for the synthesis, maturation and post-translational modification (glycosylation, phosphorylation, oxidation) of p22phox and Nox, (iii) Nox activity is promoted by the interaction between Nox and the ER chaperone PDI, (iv) some Noxes, especially Nox4, are active in ER, (v) The communication between ER and mitochondria occurs through mitochondria-associated ER membranes, which facilitates the exchange of Ca2+ and ROS between the compartments, and (vi) ER plays a critical role in redox protein folding and stress responses.

29ER stress results from a disruption in the ER protein-folding capacity, leading to the accumulation of unfolded and misfolded proteins. There is a suggestion that ER stress plays a significant role in the synergistic effects of hypertension and target organ damage.– Expressions of key molecules increase in ER stress signaling pathway, such as ATF6 (activating transcription factor-6), IRE1 (inositol requiring enzyme 1), PERK (PKR-like eukaryotic initiating factor α kinase), XBP1s (X-box-binding protein 1), ATF4 (activating transcription factor-4), and CHOP (C/EBP homologous protein) etc., leading to activation of redox signaling and hypertension.

Antioxidant system

30In addition to increased ROS/RNS production, decreased scavenging ability also contributes to oxidative stress. The vascular system have several antioxidant systems, such as the superoxide dismutase (SOD) family, catalase, the glutathione (GSH) system, thioredoxin, peroxiredoxin, selenoproteins, and ROS scavengers such as vitamins A, C, and E.– In hypertensive patients, antioxidant substances, including SOD, catalase, and GSH peroxidase etc., are significantly lower in the whole blood or peripheral mononuclear cells, when compared to normotensive individuals. After antihypertensive treatment, all these parameters can be restored.– In animal studies, it has been observed that inhibiting GSH synthesis leads to an elevation of BP in normotensive rats, and knockout of extracellular-SOD (EC-SOD) in mice results in elevated baseline BP without any other treatment. In addition, partial deficiency of SOD2, which is the mitochondrial SOD isoform, induced spontaneous hypertension in aged mice and accelerated the development of high salt-induced hypertension. These results suggest that reduced antioxidant capacity alone is enough to cause vascular dysfunction and hypertension. Catalase is another important antioxidant enzyme. Catalase facilitates a two-step reaction in which it breaks down two molecules of hydrogen peroxide into one molecule of oxygen and two molecules of water. Accumulation of catalases attenuates the progression of vascular remodeling and hypertension by reducing oxidative stress.–

Immunity/inflammation pathway

31The majority of components involved in the Immunity/inflammatory responses circulate through the blood and vasculature. And low‐grade immune response plays an important role in the initiation and maintenance of elevated BP.– Immune responses can occur in the intima, media, and adventitia of blood vessels. The luminal and microvascular endothelial cells in the intima and adventitia play a critical role in the recruitment and activation of leukocytes, which are commonly involved in the pathophysiological processes of hypertension and target organ damage. The vascular media, in contrast, is often unaffected by immune-mediated disorders. In arteries, the inflammatory response can be initiated by humoral, vasoactive hormones, mechanical factors, metabolic factors, epigenetic dysregulation, autonomic nervous system etc.– Current studies have shown that both innate and adaptive immunity are involved in the pathogenesis of hypertension,– (Fig. 7).

Innate immunity

32The innate immunity serves as the initial defense against infectious agents and also contributes significantly to the development of sterile inflammation. APCs (activation of antigen presenting cells) or PRRs (pattern recognition receptors) is the initiating step of innate immunity. MHC II (major histocompatibility complex II) in APCs can initiate activation of T or B lymphocytes and lead to adaptive immunity. While PRRs, activated by PAMPs (Pathogen-Associated Molecular Patterns) and DAMPs (Damage-Associated Molecular Patterns), mainly including TLRs (Toll-like receptors) and NLRs (NOD-like receptors), directly activate related pathways to trigger endothelial dysfunction or vasoconstriction. TLRs are a well-characterized family of membrane-bound PRRs which are expressed on the cell membrane in macrophages, dendritic cells, and mast cells.– Studies demonstrated TLR4 expression was upregulated in experimental models of Ang II and L-NAME-induced atrial hypertension.– TLR4 inhibition contributed to alleviating vascular contractility, vascular inflammation, and oxidative stress in SHRs, preventing the development of experimental hypertension.,, Stimulation of TLR4 leads to the activation of signaling pathways or transcription factor in VSMCs such as ROS, MARK, NF-κB etc.– TLR9, which recognizes circulating mitochondrial DNA, is also upregulated in the circulation of SHRs. Inhibition or knockout of TLR9 in mice can result in a reduction in systolic BP, which may be via the cardiac autonomic and baroreflex regulation., Another family of PRRs are intracellular NLRs, with the NLRP3 inflammasome being the most characterized. Activation of NLRP3 inflammasome (including NLRP3 sensory component, the adaptor protein ASC) is a powerful mediator of inflammatory response via the effector protein caspase-1, and plays a pivotal role in vascular diseases.– Study showed that NLRP3 inflammasome activation contributed to VSMC phenotypic transformation and proliferation in hypertension. And CaSR (calcium-sensing receptor)-mediated activation of the NLRP3 inflammasome in VSMCs is an important regulator of aortic remodeling in SHRs induced by Ang II.

Adaptive immunity

33T and B lymphocytes are the characterized cell types of the adaptive immune system. Animal studies proved that, inhibition of the maturation process of T and B cells by knockout of the Rag1 (recombination activating gene1) in vivo alleviated Ang II-induced and salt-sensitive hypertension., Besides, genetic knockout of the CD247 or receptor Axl (tyrosine kinase TAM family member) gene in mice attenuated salt-sensitive hypertension by attenuating glomerular and renal tubular damage or improving endothelium-dependent vasorelaxation.– Notably, study demonstrated that, it was CD8-/- mice but not MHCII-/- or CD4-/- mice that showed a blunted response in Ang II and DOCA/salt-Induced hypertension, which suggested that the role of specific T cell subtypes might be different in hypertension development. Similarly, knocking out B cell activating factor receptor (BAFF-R) also attenuated Ang II-induced BP elevation, and adoptive transfer of B cells into BAFF-R-/- mice restored Ang II-induced hypertension. The mechanisms by which T and B cells trigger hypertension have not been fully elucidated. A study has suggested that hypertension-induced sodium excretion via eNOS- and COX-2 (cyclooxygenase-2)-dependent pathways in kidneys is facilitated by the absence of lymphocyte activity, which may in turn protect against hypertension. In vascular ECs, IgG released from B cell binding to Fcγ receptors (FcγRs) and inhibiting the activity of eNOS synthase, which contributing to obesity-induced hypertension.

34In addition to T and B cells, other subtypes of T cells, mainly including T helper (Th) cells and regulatory T cells (Tregs), also contribute to the progression of hypertension by releasing pro-inflammatory factors. Th 1 cells produce IFNγ, IL-2, and TNFα; Th 2 cells produce IL-4 (interleukin-4), IL-5, IL-9, and IL-13; Th 17 cells secrete IL-17, IL-21, and IL-22. These inflammatory factors are all thought to be associated with hypertension.,– Tregs are a small subset of immune cells that play a crucial role in curbing excessive immune activation and maintaining immune homeostasis.– A decreased number and impaired function of Tregs cells have been observed in various cardiovascular diseases, including hypertension. In contrast to T cells or Th cells, differentiation and proliferation of Tregs can increase local production of anti-inflammatory cytokines (such as IL-10 and TGF-β) and reduce plasma inflammatory cytokines (such as IFN-γ, IL-6, and TNF-α) levels, which thereby attenuates the vascular immune-inflammation, vascular oxidative stress, and endothelial dysfunction, preventing against hypertension.– Interestingly, studies have shown that a decrease in Tregs significantly increases BP only in females, thereby eliminating the sex difference in the BP response to DOCA-salt, which supports the notion that the immune system contributes to sex differences in hypertension. It is worth noting that while hypertension and inflammation are physiologically connected, the impact of therapies that specifically target inflammation on BP still requires further evidence from clinic trials. IL-1β is an upstream inflammatory factor of IL-6 and CRP (C-reactive protein). IL-1β, IL-6, and CRP are considered to be closely involved in the progression of hypertension.,– However, a large clinical study have shown that the use of IL-1β antibody did not reduce the incidence of hypertension. Thus, the use of anti-inflammatory therapy to lower BP requires more in-depth study.

Sympathetic dysregulation

35The regulation of bodily functions by the sympathetic system relies on the establishment and precise connections between postganglionic sympathetic neurons and peripheral organs distributed throughout the body., Sympathetic nervous system dysfunction contributes a lot to the development of hypertension– (Fig. 8). The activation of muscle sympathetic nerve activity (SNA) is the key mechanism of sympathetic dysregulation leading to hypertension. Many forms of high BP are associated with an increase in muscle SNA, including essential hypertension,– renovascular hypertension, and pregnancy-induced hypertension, et al.

36Delivering electrical stimulation in bursts to sympathetic nerves in blood vessels can cause significant vasoconstriction. It is closely associated with norepinephrine (NE)-induced contraction of vascular smooth muscle, with NE being released by postganglionic neurons., Adrenergic receptors are distributed on the membranes of most effector cells innervated by the postganglionic fibers. Vascular SMCs have two types of adrenergic receptors, α and β. NE binding to α adrenergic receptors can cause VSMCs contraction; and it binding to β adrenergic receptors (mostly β2 receptors) can cause VSMCs relaxation. NE prefers to bind to α adrenergic receptors rather than β receptors, so it causes a vasoconstrictive effect when the vasoconstrictor fibers are excited. α adrenergic receptors on the vessels are divided into α1 and α2 receptors. And α-adrenoceptors can be classified into different subtypes, too.– Both α1 and α2-adrenoceptors are crucial in the control of vascular tone. There also exists a synergistic interaction between α1 and α2-adrenergic receptors. Following increased muscle SNA, NE binds both α1 and α2-adrenergic receptors on vascular smooth muscle, which can lead to vasoconstriction by increased [Ca2+]c and MLC phosphorylation, as well as activation of the Rho-associated kinase calcium sensitization pathway.–

Signaling pathways in cell identity

37With the widespread utilization of single-cell sequencing (scRNA-seq) technology, our understanding of the intrinsic properties of cells has shifted from single-dimensional descriptions to multi-dimensional and high-resolution depictions. Describing cell identity by key concepts such as phenotype, lineage, and state, we gain a deeper understanding of the mechanisms by which the cells can play different roles in different environments. In the vascular wall, phenotypic conversion, lineage origin, and cellular state of ECs and SMCs may all affect the vascular functions directly.

38There are two states of ECs, activated or quiescent. Activated ECs secrete MMPs, and undergo proliferation and migration, which are often closely associated with angiogenesis.,, While quiescent ECs organize themselves into a continuous monolayer and allow perfusion with blood., The production of S-2-hydroxyglutarate (S-2HG), stimulated by activated FOXO1 (transcription factor forkhead box O1), plays a key role in promoting a quiescent endothelial state., The different states of ECs can determine the longitudinal extension of blood vessels. However, no studies have reported the role of activated or quiescent ECs in vasocontriction or BP regulation yet. In addition, there exists some condition where ECs can transform into mesenchymal cells, which is called Endothelial to Mesenchymal Transition (EndMT). A variety of cellular properties will change in ECs after EndMT, such as increased permeability, enhanced migration, upregulated expression of some mesenchymal cellular markers, and enhanced ability to secret enzymes and to change the ECM environment., TGF-β (Transforming Growth Factor-β) signaling pathtway is now considered as the most significant pathway in EndMT regulation. After binding to the receptors, TGF-β can participate in the EndMT via Smad (Small Mother against Decapentalegic) and non-Smad (MAPK, ERK, etc.) pathways., Other signaling pathways, such as NOTCH and Wnt (Wingless-Related Intergration Site) pathway, can also induce EndMT., Just a few studies reported the association of EndMT with BP alterations. It was indicated that ox-LDL could promote the production of TGF-β via Lox-1/PKC-α/MMP9, and it also could induce EndMT via SMAD2/SMAD3, resulting in increased BP. And this is possibly one of the crucial mechanisms by which high blood lipids induce BP increase. Some stimulators closely associated with hypertension, such as Angiotensin II and AGEs, were also confirmed to induce EndMT, thus leading to BP increase. In addition, pro-inflammatory factors, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), have been reported to induce EndMT in human primary aortic ECs and to promote vascular calcification by downregulating BMPR2. A recent study used scRNA-seq to detect the heterogeneity and state of arterial cells in mice with salt-induced hypertension, and found that, EndMT was more commonly observed in arterial cells in hypertensive mice, compared with the control group. And this suggested that the occurrence of hypertension might be directly related to EndMT.

39VSMCs are classically characterized by the expression of four contractile- or contraction-associated proteins: TAGLN (smooth muscle 22 α/transgelin), ACTA2 (smooth muscle α-actin), MYH11 (smooth muscle myosin heavy chain 11), and CNN1 (H1-calponin). With the help of scRNA-seq, six phenotypes of VSMCs have been identified, including contractile phenotype, mesenchymal-like, fibroblast-like, macrophage-like, osteo-/chondroblast-like, and adipocyte-like phenotypes, each directly affecting the ECM with their own unique characteristics.– KLF4 (Krüppel-Like Factor 4) is considered as a key transcription factor in phenotype regulation. Although, it is theoretically possible for VSMCs switching from a contractile phenotype to other phenotypes, which may affect the contractile function of the arteries, the role of different phenotypes in arterial function and hypertension is still unknown. At present, it is clear that the osteo-/chondroblast-like phenotype is involved in the formation of arterial calfication. In a study of salt-induced hypertensive mice, VSMCs were divided into 3 groups (SMC 1, SMC 2, and SMC 3) according to their markers. SMC 1 was observed to be the most expressed group in both the hypertensive and control group. The contractile phenotype-related gene expression in SMC 1 was lower in hypertensive group than that in control group. However, The expression of KLF4 was significantly higher in hypertensive group. This indicated that part of the SMCs in aorta experienced phenotypic conversion in the salt-induced hypertensive mice, which might be associated with the occurrence of hypertension. Unfortunately, the study did not further explore which phenotype is the dominant phenotype in hypertensive arteries. Nevertheless, according to our own research data (unpublished), long-term high blood lipids level can lead to arterial remodeling and increased arterial stiffness. And the pathological mechanism may be that, induced by high blood lipids, VSMCs can convert from contratile phenotype into macrophage-like phenotype, resulting in changes in ECM composition and decreased cell contractility. However, the roles of other phenotypes, such as fibroblast-like and adipocyte-like phenotype, in vascular function and BP regulation remain to be further explored.

Vascular fibrosis and TGF-β/Smad signaling pathway

40Fibrosis refers to the excessive accumulation of connective tissue components in an organ or tissue. Vascular firobrosis is caused by the excessive deposition of the ECM components (especially fibronectin and collagen), which can result in a decrease in lumen diameter and thickening of arterial wall,, and further lead to arterial stiffness and hypertension., Although whether the two concepts of vascular fibrosis and vascular remodeling should be unified is inconclusive for the time being, they are almost consistent from the perspective of pathological changes and diseases caused. TGF-β and downstream Smad is the key signaling pathway that promotes tissue fibrosis.,, In various cells in blood vessels, such ECs, VSMCs, and fibroblasts in adventitia, the activation of TGF-β/Smad pathway can stimulate the synthesis of fibronectin and collagens, and promote their deposition in ECM, thus resulting in vascular fibrosis.,, CTGF (connective tissue growth factor) is a chaperon protein that has a synergistic effect with TGF-β to promote fibrosis. Studies showed that the activation of TGF-β signaling pathway would further upregulate CTGF gene expression, which indicated that CTGF played an important role in regulating TGF-β pathway in a positive feedback way. PAI-1 (plasminogen activator inhibitor-1) is an inhibitor of serine protease, urinary plasminogen activator (uPA) and tissue plasminogen activator (tPA). The activation of TGF-β/Smad pathway can upregulate PAI-1 gene expression. And the increase of PAI-1 in ECM will inhibit tissue proteolytic activity and collagen degradation, thus leading to protein accumulation in ECM, vascular fibrosis, and hypertension., Moreover, as mentioned above, TGF-β/Smad pathway is also a crucial pathway which promotes EndMT. It is also worth noting that, AGEs can activate Smad via MAPK pathway, independently of TGF-β, which indicates that AGEs may also be one of the causes of vascular fibrosis.

Apelin/APJ signaling pathway

41A new class of transmembrane receptor, APJ (putative receptor protein related to the angiotensin receptor), was first discovered in 1993 by O’Dowd. It has homology as high as 30% with AT1R, while it does not bind to angiotensin II. In 1998, an endogenous ligand for APJ, called apelin, was extracted from cow stomach by Tatemoto et al. Apelin is type of polypeptide hormone. APJ exists in a variety of cells such as ECs and VSMCs, and is widely expressed in large blood vessels and the vascular system of various organs.– Apelin/APJ mediates vasodilation primarily by activating the eNOS/NO pathway in ECs.– Clinical studies showed that reduced circulating Apelin was significantly associated with an increased risk of hypertension. And in animal studies, peripheral injection of Apelin can cause extensive vasodilation, as well as a decrease in blood pressure. Furthermore, Apelin/APJ also interacts with RAAS. Activation of apelin/APJ signaling pathway has an antagonistic effect towards AT1R-mediated responses.– Apelin/APJ signaling can also upregulate ACE-2 gene expression, reinforcing the conversion from Ang II to Angiotensin 1–7. This inhibition of the RAAS system is an important mechanism for Apelin to exert a protective effect on the cardiovascular system. To be mentioned, when the vascular endothelium is damaged, Apelin can act directly on the APJ of VSMCs, increasing phosphorylation of MLC and causing vasoconstriction and increased blood pressure., It can be seen that the integrity of the vascular endothelium is very important for Apelin to play its hypotensive effect. Except Apelin, recent studies also found another endogenous polypeptide ligand for APJ, Elabela (also named Toddler)., Hypertensive patients seemed to have a low level of circulating Elabela, which was strongly associated with hypertension-related vascular damage. It is currently believed that the function mechanism of Elabela is similar with that of Apelin, both of which exert their function by activating APJ-mediated downstream pathway., However, some studies showed that differences existed regarding the polypeptide structural characteristics and the functioning active groups between Elabela and Apelin. This suggested that the binding pattern of Elabela and APJ might be different from Apelin, which could be of value in pharmacology development. Both Elabela and Apelin have their latent value in antihypertensive and cardiovascular treatment.

Na+ channels and hypertension

42Alterations in circulating Na+ concentration contributes a lot to the pathology of hypertension. On the one hand, increased sodium intake in the body can lead to sodium and water retention, resulting in increased pressure to the blood vessel walls. On the other hand, it can trigger vasoconstriction or relaxation via Na+ channels.

43The Na+/Ca2+ exchangers (NCX) can link Na+ and Ca2+ metabolism and act as distal regulators of cytosolic Ca2+ levels. There are 2 types of NCXs. By one kind of NCXs, the Ca2+ transfer only depends on Na+ concentration (NCXs, including NCX1-3). While by the other kind, the Ca2+ transfer depends on both Na+ and K+ concentration (NCKXs, including NCKX 1-6).– Both NCXs and NCKXs exist in VSMCs. The transferring direction of Ca2+ (influx or outflux) via NCXs and NCKXs depends mainly on Na+, Ca2+ (and K+) gradients, and the potential across the membrane., In salt-dependent hypertensive rats, the blockage of NCX1 could cause a reduction in cytosolic Ca2+ concentration in VSMCs, thus attenuating the Ca2+ signaling and resulting in vasodilation and BP decrease. This indicated that in high salt-intake condition, NCX1 could still exert its function to mediate Ca2+ influx. Besides, NCXs in VSMCs appeared to be predominantly present in the plasma membrane adjacent to SR, which suggested that NCXs in VSMCs might indirectly regulate the Ca2+ storage in SR.

44Na+ pumps (Na, K-ATPase) can transport Na+ from intracellular to extracellular and K+ in an inverse direction against a concentration gradient by breaking down ATP, maintaining the osmotic pressure across cellular membrane. Theoretically, inhibition of the Na+ pumps activity will attenuate Na+ transporting in renal proximal tubular epithelial cells, leading to an increase in water sodium excretion and downregulating BP. Nevertheless, studies showed that inhibition of Na+ pumps was a main cause of increased peripheral vascular resistance in essential hypertension. The mechanisms by which Na+ pumps activity enhancement causes vasodilation may be related to both nitric oxide- and prostanoid-independent arterial relaxation,, and Ca2+ elevation via NCXs.– In addition, Na+ pumps can regulate inter-cell communications in vessels via cSrc-dependent Cx43 tyrosine phosphorylation, and synchronize the constriction and relaxation among VSMCs.

45Epithelial Na+ channel (ENaC), a member of DEG/ENaC family, is primarily expressed on the apical membrane of the principal cells in the aldosterone sensitive distal nephron (ASDN), where it functions as the final and rate-limiting step of renal Na+ reabsorption. Excessive ENaC activation will lead to sodium and water retention, contributing as a key mechanism to the pathology of hypertension. In vascular ECs, EnNaC activation by ALD or elevated Na+ concentration can lead to endothelial stiffness, reduced NO production, increased vascular tension and vascular remodeling.– In CNS, over-activation of ENaC and Na+ transport may lead to elevated sympathetic activity and BP increase., In dendritic cells, increased Na+ influx mediated by ENaC can promote the release of inflammatory cytokines including IL-17, and therefore upregulate BP., In addition, a recent study demonstrated that the activation of the NLRP3 inflammasome induced by Na+ is dependent on ENaC and IsoLG(isolevuglandins), and this was an important mechanism in the pathogenesis of sensitive hypertension.

Sodium-glucose co-transporter and vascular function

46Sodium-glucose co-transporter (SGLT) family refers to carrier proteins that reabsorb filtered glucose in kidneys. It is estimated that SGLT-2 is responsible for at least 80–90% filtered glucose reabsorption. Meta-analyses showed that SGLT-2 inhibition lowered SBP by 2–5 mmHg and DBP by 0.5–2 mmHg, which might have a coordinated effect with other first-line antihypertensive drugs.– The mechanisms by which SGLT-2 inhibition lowers BP include volume depletion,– negative sodium balance,, weight loss, renal protection, etc., Moreover, SGLT-2 inhibition can also regulate BP by affecting vascular fuctions. Both clinical RCTS and basic research have shown that SGLT-2 inhibition improves endothelial function as well as the vascular stiffness (measured by PWV, augmentation index, and degree of vascular fibrosis) in DM.– Potential vascular protective effects may be attributed to its alleviation of glucotoxicity by removing excessive glucose from the body, as SGLT-2 inhibitors can reduce AGE/RAGE signaling, oxidative stress levels, and the expression of inflammatory factors.– In addition, it has been suggested in some studies that SGLT2 inhibitors may suppress sympathetic activity, owing to improved glycemic control and insulin resistance as well as the decreased leptin levels. However, this mechanism remains controversial since several studies suggested that SGLT-2 inhibitors did not affect HRV or plasma adrenergic markers.,

Central nervous system

47Initially, it was thought that the central nervous system (CNS) played a limited role in regulating BP, mainly through the baroreflexes and chemoreflexes mechanisms., In fact, the CNS also orchestrates the sympathetic outflow and integrates peripheral inputs. There are numerous brain nuclei involved in regulating sympathetic tone and BP, and the connections and functional interactions among these nuclei are highly complex. The brainstem and hypothalamus regions form circuits that mediate steady-state and reflex-induced changes in sympathetic activity and BP regulation. Studies have revealed various mechanisms involving the interactions and functional connections among different cell types in the forebrain and brainstem. Recent findings suggest that Ang-II in the brain may have an impact on bone marrow-derived hematopoietic stem and progenitor cells, potentially exacerbating hypertensive vascular pathological changes.– Obesity and high-fat diets are thought to promote a chronic state of low-grade inflammation in the CNS. This is characterized by increased activation of microglia and astrocytes, as well as increased expression of genes encoding pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β). Pro-inflammatory cytokines elevation in CNS also contributes to SNA activity upregulation and the occurrence of hypertension.

Interventions

48Clinical studies have validated that targeting some vascular function-related pathways (e.g., calcium pathway, RAAS pathway, etc.) for blood pressure control is safe and effective. However, more evidence is needed to determine whether other therapeutic targets (e.g., inflammation, oxidative stress) can be utilized, too. We list below some interventions that target these pathways, both those used in clinical work already and those with potential values (Table 1).

NO-(NOsGC)-cGMP signaling

49Nitrates, such as sodium nitroprusside and nitroglycerin, are widely used in clinical settings to promote NO production and vasodilation via NO-(NOsGC)-cGMP signaling. However, nitrates commonly have short-term efficacy, and the poor tolerance limits their further use. Some drugs, reported in animal models, such as statins and Ang II receptor blockers (ARBs) may activate eNOS or increase eNOS expression to improve endothelial dysfunction.– In addition to these clinically used drugs, other antihypertensive drugs targeting NO-(NOsGC)-cGMP signaling pathway are still under exploration. As tetrahydrobiopterin (BH4) is a co-factor in eNOS activities, its supplementation may directly activate and regulate the eNOS signaling, which has attracted extensive attention. NosGC activators and stimulators are currently in clinical use or undergoing clinical development, and may potentially be tested in hypertensive patients in the near future. Some eNOS transcription enhancers, such as trans-resveratrol, are reported for their therapeutic potential as well., Phosphodiesterase (PDE) is an important substance that degrades intracellular cGMP. PDEs are classified into 11 primary isoenzyme subtypes, which are distinguished by their substrate affinity, selectivity, and regulation mechanisms. A specific and differential function in contractile VSMCs makes PDE1 inhibition an attractive novel option., Of note, ITI-214, a specific PDE1 inhibitor, has been well-tolerated by humans and a phase 2 clinical trial for heart failure has been completed.

50In addition, it is reported that lifestyle interventions should be preliminary approaches for the improvement of NO bioavailability, including a healthy diet, exercise, weight reduction, and smoking cessation. In dietary interventions, supplementation of nitrate and nitrite can exert antihypertensive effects. Another example is that cocoa can increase NO production, with a beneficial effect on hypertension. Physical activity can improve downstream NO bioavailability, both in healthy subjects and in those who are at higher cardiovascular risk, to improve endothelial function., Weight reduction and smoking cessation are also showed to be helpful for improvement of NO bioavailability.

Calcium channel signaling

51Calcium channel blockers (CCBs) are effective drugs to inhibit calcium influx. Based on their selectivity for L-type voltage-dependent transmembrane calcium channels in either the cardiac, vascular, or both tissues, CCBs can be divided into 3 groups: dihydropyridinic agents, phenilalchilaminic agents, and benzothiazepinic agents. Dihydropyridinic agents can block the voltage-dependent L-type calcium channels, which gives it vascular selectivity to preferentially block the calcium channels in VSMCs. Dihydropyridinic CCBs are now a first-line therapeutic option to treat hypertension.– Whereas verapamil and diltiazem, the representative drugs of the latter two types, have cardiac selectivity. CCBs are known to be vasodilators of small resistance arteries. When administered acutely, they can reduce total peripheral resistance and mean BP, while also increasing cardiac output. However, after chronic administration, cardiac output returns to pretreatment levels, while mean arterial pressure and systemic vascular resistance remain low.

Targeting at angiotensin-related receptors

52Four groups of drugs are clinically established to inhibit the RAAS: ACE inhibitors (ACEI), ARBs (which block the AT1 receptor), renin inhibitors and mineralocorticoid receptor blockers. Up to now, there are more than 10 types of ACEI available around the world. The main mechanism of ACEI is to limit the formation of Ang II as well as to reduce the catabolism of other vasodilator oligopeptides (such as bradykinin) by ACE. ACEI mediates the activity of the ACE2–Ang (1–7)–MAS1 axis as well., Long-time application in clinical settings have confirmed the safety and tolerability profiles for these drugs. In addition, there exist about nine ARBs for clinical use. ARBs can lead to an increase in the levels of Ang II, which can serve as a substrate of ACE2. This can result in clinical benefits due to the stimulation of the ACE2/Ang (1–7)/Mas1 axis., LCZ696 (Sacubatril/Valsartan) combines a neprilysin inhibitor moiety with a valsartan moiety, and is the first agent of the angiotensin-receptor–neprilysin (ARN) inhibitor. It can decrease BP in animals models and healthy human subjects with low incidence of adverse effects, which has been confirmed by several trials.– Notably, LCZ696 is the first drug to be approved for the treatment of heart failure (HF). Clinical trials have shown that LCZ696 is superior to enalapril (an ACEi agonists) in reducing hospitalizations in worsening HF patients and all-cause mortality in patients with left ventricular ejection fraction (LVEF) ≤40%.

53As for the ACE2/Ang (1–7)/Mas1 axis, Human recombinant ACE2, AVE 0991, and IRAP inhibitors are considered as promising drugs in hypertension treatment. Compound 21 is an AT2 agonist which can alleviate hypertension and target-organ damage. To be mentioned, there are currently vaccines under development that target the RAAS. For example, the CYT006-AngGb vaccine, which targets Ang II, has shown promising results in a phase II clinical trial by reducing BP in patients with mild to moderate hypertension without causing serious adverse events. The ATRQβ-001 vaccine, which targets the AT1R, has shown success in lowering BP in Ang II-induced hypertensive mice and SHR. However, more further studies on antihypertensive vaccines are warranted. However, vaccines may cause pain and require repeated injections, while oral medication is mature and painless.

Targeting at renin and MR

54In theory, blocking the rate-limiting enzyme, renin, can be more effective in preventing Ang II production compared to other approaches that target different components of the RAAS. Currently, the only available direct renin inhibitor for the treatment of hypertension is Aliskiren, which is an orally active non-peptide drug with high selectivity.– However, it did not achieve satisfying effects in clinical trail. And another drug, ACT‑077825, lacks evidence to confirm its effect. ACT 178882, the next generation of ACT‑077825, is still under exploration.,

55The mineralocorticoid receptor antagonist mainly refers to spironolactone, eplerenone, and canrenone. As a potassium-sparing diuretic, the efficacy of spironolactone to treat hypertension has been confirmed by RCTs. Eplerenone has a similar antihypertensive efficacy as spironolactone, but with fewer adverse effects. However, the evidence is yet relatively insufficient. Canrenone is available in some countries, but there is no large RCT demonstrating its beneficial effect., Some other drugs, such as finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has presented a promising effect in hypertension treatment., BR-4628, PF-3882845, and SM-368229 are nonsteroidal drugs still under exploration at present. Further studies are needed to confirm their safety and efficacy. As for drugs targeting at aldosterone synthase, FAD 286A, LCI699 and its second-generation drug are still under development. Besides, the expression of CYP11B1 and CYP11B2, which are responsible for the production of aldosterone and cortisol in adrenocortical cells, can be regulated post-transciptionally by dicer-dependent microRNAs (miRNAs), affecting the secretion of these hormones.

MMPs

56Antihypertensive drugs, including ACEI, ARBs, and CCBs, can regulate the MMP activity and concentration.– Administration combined with atorvastatin for 2 months induced a larger reduction in MMP-9 compared with administration alone in hypercholesterolemic subjects. To be noted, there are studies confirming an improvement in MMP reduction after weight loss and appropriate exercise.–

57MMPs inhibitors can be classified into two categories, hydroxamate-based inhibitors and non-hydroxamate MMP inhibitors. Collagen-based peptidomimetic hydroxamates include marimastat, ilomastat, and batimastat. Batimastat is the first MMP inhibitor studied in clinical trials. It is a low-molecular-mass hydroxamate derivative with low water solubility. It exerts its inhibitory effect by directly binding to Zn2+ ions in the active site of several MMPs, including MMP1, MMP2, MMP7, and MMP9. Non-hydroxamate MMP inhibitors, including rebimastat, tanomastat, etc. Rebimastat is a broad-spectrum MMP inhibitor which contains a thiol zinc-binding group. Tanomastat contains a thioether zinc-binding group and a biphenyl deep-pocket-binding segment, and it has been confirmed in trials to be well-tolerated. However, no specific MMPs inhibitors have been used to treat vascular remodeling or hypertension. In treatment of cancer, despite the promising preclinical data supporting the use of MMP inhibitors as anticancer drugs, it failed to achieve the desired results in clinical settings. Similarly, more evidence is needed for the utilization of MMPs inhibitors in the treatment of hypertension.

AGEs

58Levels of AGEs can be reduced by comsuming a diet low in AGEs, which involves reducing the intake of glucose, red meat, butter, cream, and other sweetened fatty foods but increasing the proportion of grains, vegetables, fruits, and milk in the diet. From the perspective of AGE formation, there are drugs such as aminoguanidine, vitamins, ACEI, metformin, acidic ingredients, and pomegranate that can suppress its production. Animal studies and clinical trials proved that, alagebrium and ALT-711 could degrade AGE.– RAGE expression can be suppressed by numerous agents, such as statins, ACEI and ARBs. Besides, statins, ACEI, ARBs, antidiabetic drugs, and systemic administration of recombinant sRAGE have been reported to elevate the levels of both sRAGE and esRAGE.

Calcification

59An effective measure to prevent calcification in murine models is the administration of exogenous pyrophosphate.– Moreover, it has been shown that inhibition of TNAP (tissue-nonspecific alkaline phosphatase)– and exogenous administration of ENPP1 can also prevent vascular calcification. Nevertheless, the effects of these treatments still need to be further discussed in humans. SNF472 is an intravenous formulation of myo-inositol hexaphosphate. It can inhibit the formation and growth of hydroxyapatite crystals through a novel pathway, which is the final common step in the pathophysiology of vascular calcification, selectively and directly., Ferroptosis has emerged as a potential therapeutic target for anti-calcification intervention. Metformin can exert anti-ferroptotic effects and attenuate hyperlipidemia-associated vascular calcification. Moreover, recent evidence suggests that autophagy may have a direct protect effect against vascular calcification.

60There are also some other potential drugs or treatment targets. For example, Valporic acid, an inducer of autophagy, has been demonstrated to inhibit VSMC calcification in vitro. Rapamycin has been shown to alleviate vascular calcification in DBA/2 mice with diabetes. XBP1u (unspliced X-box binding protein 1), an endogenous inhibitor, can promote β-catenin ubiquitination degradation and attenuate vascular calcification. Suppressing activation of NF-κB, zinc can potentially protect against phosphate-induced arterial calcification. Furthermore, there is evidence to suggest that higher intake of dietary zinc is related to a reduced risk of severe abdominal aortic calcification.

Anti-oxidative stress therapy

61Evidence is mounting that antioxidants may paly a crucial role in the management of hypertension. They have also been shown to improve endothelial function, attenuate vascular remodeling, and lower arterial stiffness in some models., Antioxidants compounds such as vitamins E (or α-tocopherol) and vitamins C (or ascorbic acid), polyphenols and some clinical hypertensive drugs may have antioxidative pleiotropic effects. Vitamins E is a promising drug with its potenial as an antioxidant. Several clinical trials have demonstrated its important role in prevention of hypertension., Vitamins C is a potent water-soluble antioxidant which may improve vasodilation response in hypertension by increasing eNOS activity and reducing ROS levels.–

62Polyphenols have been shown to have antihypertensive effects and to improve endothelial function, which may be due to its ability to inhibit ROS generating enzymes and to enhance GSH., RAAS inhibitors such as ACEI and ARBs can effectively lower NADPH oxidase levels. In addition, treatment with ACEI and ARBs has been associated with an increase in superoxide dismutase activity., Antioxidant effect of dihydropyridine CCBs can contribute to the prevention and medication of endothelial dysfunction as well. Nifedipine and nicardipine have been demonstrated to prevent ROS-induced endothelial dysfunction directly and improve endogenous antioxidants in cultured cell lines. Benidipine has a protective effect on human endothelial cells via reducing oxidative damage induced by ox-LDL which triggers ROS generation. There are also some drugs that have shown antioxidant and antihypertensive effects in studies, such as Genistein, N-acetylcysteine(NAC), and Allopurinol., Nevertheless, their functions need to be further elucidated.

Anti-inflammation

63RAAS-suppressing drugs have been shown to possess potent anti-inflammatory effects. It is noteworthy that, such anti-inflammatory effects may be unrelated to their BP-lowering effects and instead may be due to their ability to directly counteract the pro-inflammatory effects induced by Ang II. Statins may have anti-inflammatory effects and can lead to a small decrease in systolic BP in patients with hypercholesterolemea, by reducing pro-inflammatory cytokines levels. Some immunosuppressant drugs have potential as a treatment for hypertension, too. Mycophenolate mofetil has been found to reduce BP in SHR, and in Dahl salt-sensitive rats., Lifestyle also affects BP by alleviating inflammation. Mediterranean diet is closely related to anti-inflammatory effects and endothelial function. A regular and moderate aerobic physical exercise can also present anti-inflammatory effects. However, whether anti-inflammation can be used to treat hypertension clinically it is still doubtful. Nonsteroidal anti-inflammatory drugs can lead to an increase in BP by promoting sodium retention., Furthermore, Canakinumab, the anti-IL-1β monoclonal antibody, reduced inflammatory factors including IL-1β, IL-6, hs-CRP in patients with atherosclerotic disease, but it did not reduce the incidence of hypertension nor down-regulated BP at 3, 6, or 12 months.,– However, study suggested that plasma IL-1β concentration elevated in hypertensive patients, no significant change was observed in its receptors levels. And it indicated that, without IL-1β-related indicators of cellular immune activation, the reduction in plasma IL-1β level alone might be insufficient to reflect the levels of other inmmune activatioin. In addition, inflammation in hypertensive patients is considered to be low-level and chronic inflammatory stimuli. The longest follow-up duration in the CANTOS study was 12 months. It is rather unclear when vascular remodeling occurs in patients with hypertension. The 1-year period seems to be relatively short, so the follow-up time of this study may be responsible for the contradiction. These may be the reasons why anti-IL-1β failed to reduce BP. In all, specific anti-inflammatory drugs did not achieve significant antihypertensive effects yet in clinical studies. Whether hypertension can be treated with anti-inflammatory drugs remains controversial.

Sympathetic nervous system

64Clinically, it is one of the important means to control BP by restricting the effect of released NE, with drugs competitively binding to adrenergic receptors. Selective α1-adrenoceptor antagonists mainly include prazosin, terazosin, and doxazosin. α2-adrenergic agonists, such as clonidine, can stimulate α2-adrenoceptor in the brainstem and subsequently reduce sympathetic outflow from the CNS, leading to a decrease in BP. Nonselective α-adrenergic antagonists, phentolamine and phenoxybenzamine, were primarily administered parenterally for the management of hypertensive crisis. The reduction in plasma NE is directly associated with the hypotensive effect. Clonidine can lower BP via cardiac output and total peripheral resistance. Moxonidine and rilmenidine, which are imidazoline-1 receptor agonists, have been shown to be equally effective as other classes of antihypertensive agents, with their mechanism of action involving a reduction in sympathetic outflow from the CNS. In addition, their side effects like sedation, dry mouth, and rebound hypertension, were not commonly observed in studies.– β-adrenergic receptor antagonists, like propranolol, can lower BP by decreasing myocardial contractility, heart rate, and cardiac output. Moreover, β-adrenergic receptor antagonists can improve the prognosis of chronic HF, coronary heart disease and other cardiovascular diseases. Therefore, β-adrenergic receptor antagonists are often used as first-line drugs for hypertension complicated with chronic HF and coronary heart disease.

65Intervening sympathetic activity by invasive means can also achieve the purpose of controlling BP. Surgical interventions such as thoracic sympathectomy were already abandoned due to their high mortality rate and relatively high incidence of complications. Recent treatments for hypertension have focused on device-based approaches, such as renal denervation and baroreflex activation therapy, to modify the SNS. Although renal denervation seemed fail to cure resistant hypertension, based on the sobering results from SYMPLICITY-HTN 3, it remains a promising therapeutic method with huge potential. Baroreflex activation therapy is also considered as an alternative choice for resistant hypertension.

66Lifestyle interventions can reduce SNA and BP in hypertensive patients as well. Neurogenic components contribute much to obesity-related hypertension. Exercise training and/or low caloric intake can lead to weight loss and down-regulate SNA., The effects of exercise involve up-regulating central antioxidants concentrations, reducing pro-oxidant levels, and increasing central nitric oxide synthase activity. Chronic psychosocial stress is also associated with highly activated SNS and abnormal BP. Stress reduction measures are supposed to be effective in reducing SNA and lowering BP in hypertensives. Besides, device-guided, home-based slow and deep breathing training has been shown to effectively reduce BP in patients with hypertension as well.–

Biomarkers

67Biomarkers can be used to predict disease development, identify disease, define disease severity, and assess prognosis and treatment effect. The application of biomarkers in clinical settings contributes greatly to disease monitoring and prognosis prediction. For example, tradional markers like CRP can be used to predict the incidence of hypertension, sortlin is able to predict the onset of vascular dysfunction and hypertension, APCs and Klotho can be used to identify salt-sensitive hypertension,, platelets and circulating CD34-positive cells can be important indicators of vicious cyclical activity between hypertension and endothelial dysfunction, and high-sensitivity cardiac troponin T or NT-proBNP can better guide patients in BP control after being incorporated into risk assessment algorithms. As for urinary microalbumin, it is not only applied to BP monitoring, but also to the hypertension-related risk of cardiovascular diseases and mortality assessment.

68Except predicting the initiation and progression of diseases, it is also promising to determine potential treatment targets in the biomarkers-related signaling pathways. Sortlin is a member of the vacuolar protein sorting 10 (VPS10P) family of receptors. It was recently reported to induce endothelial dysfunction of mesenteric arteries via activating NOX2 (NADPH oxidase 2) isoform, which could be prevented by ASMase (acid sphingomyelinase) or sphingosine kinase 1 knockdow. Addtionally, patients with hypertension, especially those with uncontrolled BP, exhibited an increase in plasma ASMase activity and plasma sortilin concentration. Similarly, some other newly discovered circulating proteins (such as Sphingosine-1-Phosphate, Klotho) and some small molecules (such as non-coding RNAs,, microvesicles) can function as predicting biomarkers, as well as potential treatment targets.

Conclusion and perspectives

69An updated Mosaic Theory has been proposed to explain the pathogenesis of hypertension. According to this theory, hypertension is believed to be a response to various combinations of traits and stressors. The new Mosaic Theory emphasizes other factors such as oxidative stress, sympathetic activation, inflammation, genetics, microbiome, renal mechanisms, and salt intake, in addition to vascular fuction. Although the interaction of these factors results in a complex pathogenesis of hypertension, resembling a network, vascular function is undoubtedly the direct cause of BP elevation. BP control in clinical practice is mainly based on targeting vascular function, such as RAAS inhibitors, CCBs, nitrates, etc. On the contrary, the therapeutic potentials of other factors, except renal function, have not been well elucidated in clinical use or in large clinical studies.

70In vascular function, the interaction network formed by molecular pathways is also complex. We divide the molecular pathways that act on blood vessels into two categories (Fig. 9a) One indirectly affects vascular sympathetic activity, such as RAAS, immunity, and redox signaling. The other directly affects vascular functions, such as calcium signaling, NO-(NOsGC)-cGMP, vascular remodeling, etc. The former type of interaction has a complex network and mainly induces vasoconstriction by regulating the direct pathway, for example, sympathetic disorders mainly trigger vasoconstriction by activating calcium channels, RAAS activates calcium channels and triggers vascular remodeling.

71Long-term control of BP is currently the main strategy for treating hypertension and reducing target organ damage in hypertension. In therapeutic strategies targeting blood vessels, there are mainly three ways (Fig. 9b): lifestyle interventions, pharmacological therapy, and invasive interventions. Lifestyle interventions, especially diet and exercise, can affect vascular function and BP in almost all pathways. Llifestyle modification is recommended as the first line of antihypertensive treatment., Drug therapy is the basis of BP control in clinical work. RAAS inhibitors, and CCBs are first-line antihypertensive drugs; β-blockers and α-adrenergic antagonists play important roles in the treatment of sympathetic-induced hypertension; Nitrates are commonly used in hypertensive emergencies and sub-emergency. Invasive intervention brings new perspective on the treatment of resistant hypertension. As for the utilization of molecular pathways concerning vascular functions in guiding the treatment of hypertension, the efficacy of calcium signaling, NO-(NOsGC)-cGMP, RAAS, and sympathetic activity have been clearly demonstrated in clinical practice. Nevertheless, drugs targeting vascular remodeling, redox signaling, and immunity are still under studying.

72For the next research direction, translating basic study findings on vascular remodeling, redox signaling, and immunity to clinical applications is a priority. Especially vascular remodeling. From the current study, vascular remodeling is difficult to reverse, and it may be closely related to refractory hypertension. Since the state and function of cells (especially secretory function) directly affect the ECM, the elucidation of cell identity and the rewriting of cell fate may be crucial to make a breakthrough in vascular remodeling. Therefore, completing vascular cell maps in different pathological conditions should be one important direction in further studies. On the other hand, although current antihypertensive drugs are effective, many people with hypertension still struggle to achieve target BP levels, and the optimal BP goal also remains controversial.– The importance of reducing cardiovascular events should be emphasized in BP control. Therefore, achieving BP targets while simultaneously preventing cardiovascular events is the main goal in hypertension treatment. As discussed above, searching for suitable biomarkers and forming new diagnosis and treatment protocols is promising to save the problem (Fig. 10). Urinary microalbumin is a successful case of biomarkers applied to monitoring BP control as well as predicting cardiovascular events, it is now a classic indicator widely accepted by clinical guidelines for hypertension. Utilization of high-throughput sequencing and machine learning are cutting-edge methods to further mine the role of biomarkers.,

73It is worth mentioning that hypertension has been defined as a disease for over a century. However, modern medicine tends to view hypertension as a risk factor for vascular disease rather than a disease in itself. The essence of controlling BP is to reduce cardiovascular events, similar to controlling blood lipids and glucose. We need to be aware that the molecular mechanism of hypertension is essentially a molecular mechanism of vascular dysfunction and/or vascular volume. Understanding this is particularly important for in-depth research on the signaling pathways of hypertension.

74In conclusion, our review demonstrated the signaling pathways involved in the vascular function and hypertension, and summarized therapeutic methods of hypertension which target at vascular function. In addition, we raised unresolved questions in vascular function and hypertension, and presented our own perspectives. It is expected to enlighten other researchers on the future research directions.

References 669

1.
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 2020;16:223-237.
Not in our library10.1038/s41581-019-0244-2
2.
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants · 2021
Corrected
3.
Sudharsanan N, et al. Variation in the proportion of adults in need of blood pressure-lowering medications by hypertension care guideline in low- and middle-income countries: a cross-sectional study of 1 037 215 individuals from 50 nationally representative surveys. Circulation. 2021;143:991-1001.
Not in our library10.1161/circulationaha.120.051620
4.
Wenceslau CF, et al. Guidelines for the measurement of vascular function and structure in isolated arteries and veins. Am. J. Physiol. Heart Circ. Physiol. 2021;321:H77-h111.
Not in our library10.1152/ajpheart.01021.2020
5.
Augustin HG, Koh GY. Organotypic vasculature: from descriptive heterogeneity to functional pathophysiology. Science. 2017;357:eaal2379.
Not in our library10.1126/science.aal2379
6.
Nagy N, et al. Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. Circulation. 2010;122:2313-2322.
Not in our library10.1161/circulationaha.110.972653
7.
Dogné S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb. Vasc. Biol. 2018;38:1427-1439.
Not in our library10.1161/atvbaha.118.310839
8.
Vascular Endothelial Cell Biology: An Update · 2019
No notice
9.
Rafii S, Butler JM, Ding BS. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529:316-325.
Not in our library10.1038/nature17040
10.
Ambrosino P, et al. Mechanisms and clinical implications of endothelial dysfunction in arterial hypertension. J. Cardiovasc. Dev. Dis. 2022;9:136.
Not in our library10.3390/jcdd9050136
11.
Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005;97:1093-1107.
Not in our library10.1161/01.res.0000191547.64391.e3
12.
Durgin BG, Straub AC. Redox control of vascular smooth muscle cell function and plasticity. Lab. Investig. 2018;98:1254-1262.
Not in our library10.1038/s41374-018-0032-9
13.
Dinardo CL, et al. Variation of mechanical properties and quantitative proteomics of VSMC along the arterial tree. Am. J. Physiol. Heart Circ. Physiol. 2014;306:H505-16.
Not in our library10.1152/ajpheart.00655.2013
14.
Lacolley P, Regnault V, Segers P, Laurent S. Vascular smooth muscle cells and arterial stiffening: relevance in development, aging, and disease. Physiol. Rev. 2017;97:1555-1617.
Not in our library10.1152/physrev.00003.2017
15.
Pauly RR, et al. Experimental models that mimic the differentiation and dedifferentiation of vascular cells. Circulation. 1992;86:Iii68-73.
Not in our library
16.
Majesky MW. Vascular development. Arterioscler Thromb. Vasc. Biol. 2018;38:e17-e24.
Not in our library10.1161/atvbaha.118.310223
17.
Ribeiro-Silva JC, Nolasco P, Krieger JE, Miyakawa AA. Dynamic crosstalk between vascular smooth muscle cells and the aged extracellular matrix. Int. J. Mol. Sci. 2021;22:10175.
Not in our library10.3390/ijms221810175
18.
Majesky MW. Adventitia and perivascular cells. Arterioscler Thromb. Vasc. Biol. 2015;35:e31-e35.
Not in our library10.1161/atvbaha.115.306088
19.
Stenmark KR, et al. The adventitia: essential regulator of vascular wall structure and function. Annu. Rev. Physiol. 2013;75:23-47.
Not in our library10.1146/annurev-physiol-030212-183802
20.
Rizzoni D, et al. Prognostic significance of small-artery structure in hypertension. Circulation. 2003;108:2230-2235.
Not in our library10.1161/01.cir.0000095031.51492.c5
21.
De Ciuceis C, et al. Structural alterations of subcutaneous small-resistance arteries may predict major cardiovascular events in patients with hypertension. Am. J. Hypertens. 2007;20:846-852.
Not in our library10.1016/j.amjhyper.2007.03.016
22.
Rizzoni D, et al. Morning rise of blood pressure and subcutaneous small resistance artery structure. J. Hypertens. 2007;25:1698-1703.
Not in our library10.1097/hjh.0b013e328172dc41
23.
Mathiassen ON, et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J. Hypertens. 2007;25:1021-1026.
Not in our library10.1097/hjh.0b013e32805bf8ed
24.
Buus NH, et al. Small artery structure during antihypertensive therapy is an independent predictor of cardiovascular events in essential hypertension. J. Hypertens. 2013;31:791-797.
Not in our library10.1097/hjh.0b013e32835e215e
25.
Vascular smooth muscle contraction in hypertension · 2018
No notice
26.
Briones AM, Arribas SM, Salaices M. Role of extracellular matrix in vascular remodeling of hypertension. Curr. Opin. Nephrol. Hypertens. 2010;19:187-194.
Not in our library10.1097/mnh.0b013e328335eec9
27.
Zanoli L, et al. Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. J. Hypertens. 2020;38:1682-1698.
Not in our library10.1097/hjh.0000000000002508
28.
Hai CM, Murphy RA. Ca2+, crossbridge phosphorylation, and contraction. Annu. Rev. Physiol. 1989;51:285-298.
Not in our library10.1146/annurev.ph.51.030189.001441
29.
Kuo IY, Ehrlich BE. Signaling in muscle contraction. Cold Spring Harb. Perspect. Biol. 2015;7:a006023.
Not in our library10.1101/cshperspect.a006023
30.
Ottolini M, Sonkusare SK. The calcium signaling mechanisms in arterial smooth muscle and endothelial cells. Compr. Physiol. 2021;11:1831-1869.
Not in our library10.1002/cphy.c200030
31.
Hill-Eubanks DC, Werner ME, Heppner TJ, Nelson MT. Calcium signaling in smooth muscle. Cold Spring Harb. Perspect. Biol. 2011;3:a004549.
Not in our library10.1101/cshperspect.a004549
32.
Cribbs LLT-type. Ca2+ channels in vascular smooth muscle: multiple functions. Cell Calcium. 2006;40:221-230.
Not in our library10.1016/j.ceca.2006.04.026
33.
Weiss S, Oz S, Benmocha A, Dascal N. Regulation of cardiac L-type Ca2+ channel CaV1.2 via the β-adrenergic-cAMP-protein kinase A pathway: old dogmas, advances, and new uncertainties. Circ. Res. 2013;113:617-631.
Not in our library10.1161/circresaha.113.301781
34.
Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature. Hypertension. 2004;44:796-799.
Not in our library10.1161/01.hyp.0000148303.98066.ab
35.
Uehata M, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
Not in our library10.1038/40187
36.
Lincoln TM. Myosin phosphatase regulatory pathways. Circ. Res. 2007;100:10-12.
Not in our library10.1161/01.res.0000255894.25293.82
37.
Soloviev AI, Bershtein SA. The contractile apparatus in vascular smooth muscle cells of spontaneously hypertensive rats possess increased calcium sensitivity: the possible role of protein kinase C. J. Hypertens. 1992;10:131-136.
Not in our library10.1097/00004872-199202000-00004
38.
Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629-635.
Not in our library10.1038/nature01148
39.
Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol. Rev. 2013;93:269-309.
Not in our library10.1152/physrev.00003.2012
40.
Ishizaki T, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15:1885-1893.
Not in our library10.1002/j.1460-2075.1996.tb00539.x
41.
Matsui T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208-2216.
Not in our library10.1002/j.1460-2075.1996.tb00574.x
42.
Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ. Res. 2016;118:352-366.
Not in our library10.1161/circresaha.115.306532
43.
Kimura K, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245-248.
Not in our library10.1126/science.273.5272.245
44.
Kureishi Y, et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J. Biol. Chem. 1997;272:12257-12260.
Not in our library10.1074/jbc.272.19.12257
45.
Rho-associated kinase and zipper-interacting protein kinase, but not myosin light chain kinase, are involved in the regulation of myosin phosphorylation in serum-stimulated human arterial smooth muscle cells. · 2019
Not checked
46.
Noma K, et al. Smoking, endothelial function, and Rho-kinase in humans. Arterioscler Thromb. Vasc. Biol. 2005;25:2630-2635.
Not in our library10.1161/01.atv.0000189304.32725.bd
47.
Noma K, et al. Smoking activates rho-kinase in smooth muscle cells of forearm vasculature in humans. Hypertension. 2003;41:1102-1105.
Not in our library10.1161/01.hyp.0000067062.92836.9e
48.
Lee MW, Severson DL. Signal transduction in vascular smooth muscle: diacylglycerol second messengers and PKC action. Am. J. Physiol. 1994;267:C659-78.
Not in our library10.1152/ajpcell.1994.267.3.c659
49.
Steinberg SF. Structural basis of protein kinase C isoform function. Physiol. Rev. 2008;88:1341-1378.
Not in our library10.1152/physrev.00034.2007
50.
Pucci ML, et al. Vascular responsiveness to nitric oxide synthesis inhibition in hypertensive rats. Hypertension. 1994;23:744-751.
Not in our library10.1161/01.hyp.23.6.744
51.
Bruschi G, Bruschi ME, Capelli P, Regolisti G, Borghetti A. Increased sensitivity to protein kinase C activation in aortas of spontaneously hypertensive rats. J. Hypertens. Suppl. 1988;6:S248-51.
Not in our library10.1097/00004872-198812040-00075
52.
Dimopoulos GJ, Semba S, Kitazawa K, Eto M, Kitazawa T. Ca2+-dependent rapid Ca2+ sensitization of contraction in arterial smooth muscle. Circ. Res. 2007;100:121-129.
Not in our library10.1161/01.res.0000253902.90489.df
53.
Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
Not in our library10.1161/01.cir.87.5.1468
54.
Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 1990;323:22-27.
Not in our library10.1056/nejm199007053230105
55.
Münzel T, et al. Physiology and pathophysiology of vascular signaling controlled by guanosine 3’,5’-cyclic monophosphate-dependent protein kinase [corrected]. Circulation. 2003;108:2172-2183.
Not in our library10.1161/01.cir.0000094403.78467.c3
56.
Li Q, Youn JY, Cai H. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J. Hypertens. 2015;33:1128-1136.
Not in our library10.1097/hjh.0000000000000587
57.
Gauthier C, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J. Clin. Invest. 1998;102:1377-1384.
Not in our library10.1172/jci2191
58.
Szöcs K, et al. Increased superoxide production in nitrate tolerance is associated with NAD(P)H oxidase and aldehyde dehydrogenase 2 downregulation. J. Mol. Cell Cardiol. 2007;42:1111-1118.
Not in our library10.1016/j.yjmcc.2007.03.904
59.
Buckley BJ, Mirza Z, Whorton AR. Regulation of Ca(2+)-dependent nitric oxide synthase in bovine aortic endothelial cells. Am. J. Physiol. 1995;269:C757-C765.
Not in our library10.1152/ajpcell.1995.269.3.c757
60.
McDuffie JE, Coaxum SD, Maleque MA. 5-Hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures. Proc. Soc. Exp. Biol. Med. 1999;221:386-390.
Not in our library10.1046/j.1525-1373.1999.d01-97.x
61.
Awolesi MA, Widmann MD, Sessa WC, Sumpio BE. Cyclic strain increases endothelial nitric oxide synthase activity. Surgery. 1994;116:439-444.
Not in our library
62.
Mollnau H, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 2002;90:e58-e65.
Not in our library10.1161/01.res.0000012569.55432.02
63.
Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Disco. 2008;7:156-167.
Not in our library10.1038/nrd2466
64.
Bescós R, Sureda A, Tur JA, Pons A. The effect of nitric-oxide-related supplements on human performance. Sports Med. 2012;42:99-117.
Not in our library10.2165/11596860-000000000-00000
65.
Huang PL, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
Not in our library10.1038/377239a0
66.
Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure · 2021
No notice
67.
Straub AC, et al. Endothelial cell expression of haemoglobin α regulates nitric oxide signalling. Nature. 2012;491:473-477.
Not in our library10.1038/nature11626
68.
Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur. Heart J. 2012;33:829-837.
Not in our library10.1093/eurheartj/ehr304
69.
Rochette L, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharm. Ther. 2013;140:239-257.
Not in our library10.1016/j.pharmthera.2013.07.004
70.
Feil R, Kemp-Harper B. cGMP signalling: from bench to bedside. EMBO Rep. 2006;7:149-153.
Not in our library10.1038/sj.embor.7400627
71.
Surks HK, et al. Regulation of Myosin Phosphatase by a Specific Interaction with cGMP- Dependent Protein Kinase Iα. Science. 1999;286:1583-1587.
Not in our library10.1126/science.286.5444.1583
72.
Weber S, et al. Rescue of cGMP kinase I knockout mice by smooth muscle–specific expression of either isozyme. Circ. Res. 2007;101:1096-1103.
Not in our library10.1161/circresaha.107.154351
73.
Feil R, et al. Functional reconstitution of vascular smooth muscle cells with cGMP-dependent protein kinase I isoforms. Circ. Res. 2002;90:1080-1086.
Not in our library10.1161/01.res.0000019586.95768.40
74.
Surks HK. cGMP-dependent protein kinase I and smooth muscle relaxation. Circ. Res. 2007;101:1078-1080.
Not in our library10.1161/circresaha.107.165779
75.
Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A. Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J. Biol. Chem. 2002;277:6214-6222.
Not in our library10.1074/jbc.m110508200
76.
Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension. 1999;33:569-574.
Not in our library10.1161/01.hyp.33.1.569
77.
Arribas SM, Hinek A, González MC. Elastic fibres and vascular structure in hypertension. Pharm. Ther. 2006;111:771-791.
Not in our library10.1016/j.pharmthera.2005.12.003
78.
Chirinos JA, Segers P, Hughes T, Townsend R. Large-artery stiffness in health and disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019;74:1237-1263.
Not in our library10.1016/j.jacc.2019.07.012
79.
Vascular biology of ageing—Implications in hypertension · 2015
No notice
80.
Lakatta EG. The reality of aging viewed from the arterial wall. Artery Res. 2013;7:73-80.
Not in our library10.1016/j.artres.2013.01.003
81.
Yasmin, et al. Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness. Arterioscler Thromb. Vasc. Biol. 2005;25:372-378.
Not in our library10.1161/01.atv.0000151373.33830.41
82.
Basalyga DM, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation. 2004;110:3480-3487.
Not in our library10.1161/01.cir.0000148367.08413.e9
83.
Basalyga DM, et al. Elastin degradation and calcification in an abdominal aorta injury model. Circulation. 2004;110:3480-3487.
Not in our library10.1161/01.cir.0000148367.08413.e9
84.
Struewing IT, Durham SN, Barnett CD, Mao CD. Enhanced endothelial cell senescence by lithium-induced matrix metalloproteinase-1 expression. J. Biol. Chem. 2009;284:17595-17606.
Not in our library10.1074/jbc.m109.001735
85.
Agrinier N, et al. Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study. Fundam. Clin. Pharmacol. 2013;27:572-580.
Not in our library10.1111/j.1472-8206.2012.01053.x
86.
Morillas P, et al. Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage. J. Hypertens. 2013;31:1611-1617.
Not in our library10.1097/hjh.0b013e3283614c1c
87.
Belo VA, Parente JM, Tanus-Santos JE, Castro MM. Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension. Biochem. Pharm. 2016;118:50-58.
Not in our library10.1016/j.bcp.2016.08.012
88.
Wang M, et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am. J. Pathol. 2005;167:1429-1442.
Not in our library10.1016/s0002-9440(10)61229-1
89.
Ceron CS, et al. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol. 2012;31:261-270.
Not in our library10.1016/j.matbio.2012.01.009
90.
Djurić T, Živković M, Stanković A, Mečanin S, Alavantić D. Endothelial NOS G894 T and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian population. J. Clin. Lab Anal. 2005;19:241-246.
Not in our library10.1002/jcla.20085
91.
Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ. Res. 2003;92:1254-1261.
Not in our library10.1161/01.res.0000076891.24317.ca
92.
Onal IK, et al. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur. J. Intern. Med. 2009;20:369-372.
Not in our library10.1016/j.ejim.2008.10.003
93.
Lacerda L, Faria AP, Fontana V, Moreno H, Sandrim V. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension. Arq. Bras. Cardiol. 2015;105:168-175.
Not in our library10.5935/abc.20150060
94.
Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl. Sci. 2017;147:1-73.
Not in our library10.1016/bs.pmbts.2017.02.005
95.
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-573.
Not in our library10.1016/j.cardiores.2005.12.002
96.
Cerofolini L, Fragai M, Luchinat C. Mechanism and Inhibition of Matrix Metalloproteinases. Curr. Med Chem. 2019;26:2609-2633.
Not in our library10.2174/0929867325666180326163523
97.
Structure and Function of Human Matrix Metalloproteinases · 2020
No notice
98.
Berg G, Barchuk M, Miksztowicz V. Behavior of metalloproteinases in adipose tissue, liver and arterial wall: an update of extracellular matrix remodeling. Cells. 2019;8:158.
Not in our library10.3390/cells8020158
99.
Jiang L, et al. Calpain-1 regulation of matrix metalloproteinase 2 activity in vascular smooth muscle cells facilitates age-associated aortic wall calcification and fibrosis. Hypertension. 2012;60:1192-1199.
Not in our library10.1161/hypertensionaha.112.196840
100.
Sasaki T, et al. Matrix metalloproteinase-2 deficiency impairs aortic atherosclerotic calcification in ApoE-deficient mice. Atherosclerosis. 2013;227:43-50.
Not in our library10.1016/j.atherosclerosis.2012.12.008
101.
Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications · 2016
No notice
102.
Wang M, Kim SH, Monticone RE, Lakatta EG. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension. 2015;65:698-703.
Not in our library10.1161/hypertensionaha.114.03618
103.
Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension. 2013;61:488-493.
Not in our library10.1161/hypertensionaha.111.00055
104.
Fernandez-Patron C, et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ. Res. 2000;87:670-676.
Not in our library10.1161/01.res.87.8.670
105.
Nagareddy PR, et al. Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br. J. Pharm. 2012;165:705-715.
Not in our library10.1111/j.1476-5381.2011.01583.x
106.
Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schönbein GW. Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2010;299:H25-35.
Not in our library10.1152/ajpheart.00620.2009
107.
Kalogeris TJ, Korthuis RJ. Vascular receptors as new substrates for matrix metalloproteinases in hypertension and other inflammatory states. Am. J. Physiol. Heart Circ. Physiol. 2010;299:H13-5.
Not in our library10.1152/ajpheart.00378.2010
108.
Li K, Tay FR, Yiu CKY. The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharm. Ther. 2020;207:107465.
Not in our library10.1016/j.pharmthera.2019.107465
109.
Cui Y, et al. Platelet-derived growth factor-BB induces matrix metalloproteinase-2 expression and rat vascular smooth muscle cell migration via ROCK and ERK/p38 MAPK pathways. Mol. Cell Biochem. 2014;393:255-263.
Not in our library10.1007/s11010-014-2068-5
110.
Wang Y, et al. Inhibitory effects of cycloastragenol on abdominal aortic aneurysm and its related mechanisms. Br. J. Pharm. 2019;176:282-296.
Not in our library10.1111/bph.14515
111.
Sun HJ, et al. Salusin-β promotes vascular smooth muscle cell migration and intimal hyperplasia after vascular injury via ROS/NFκB/MMP-9 pathway. Antioxid. Redox Signal. 2016;24:1045-1057.
Not in our library10.1089/ars.2015.6475
112.
Stone JD, et al. AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury. Am. J. Physiol. Heart Circ. Physiol. 2013;304:H369-81.
Not in our library10.1152/ajpheart.00446.2012
113.
Endo H, Owada S, Inagaki Y, Shida Y, Tatemichi M. Glucose starvation induces LKB1-AMPK-mediated MMP-9 expression in cancer cells. Sci. Rep. 2018;8:10122.
Not in our library10.1038/s41598-018-28074-w
114.
Lim WW, et al. Inhibition of IL11 signaling reduces aortic pathology in murine marfan syndrome. Circ. Res. 2022;130:728-740.
Not in our library10.1161/circresaha.121.320381
115.
Wang Y, et al. Involvement of macrophage-derived exosomes in abdominal aortic aneurysms development. Atherosclerosis. 2019;289:64-72.
Not in our library10.1016/j.atherosclerosis.2019.08.016
116.
Chang S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006;126:321-334.
Not in our library10.1016/j.cell.2006.05.040
117.
Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 1998;37:586-600.
Not in our library10.1016/s0008-6363(97)00233-2
118.
Chaudhuri J, et al. The role of advanced glycation end products in aging and metabolic diseases: bridging association and causality. Cell Metab. 2018;28:337-352.
Not in our library10.1016/j.cmet.2018.08.014
119.
Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol. Metab. Clin. North Am. 2013;42:697-719.
Not in our library10.1016/j.ecl.2013.07.005
120.
McNair E, Qureshi M, Prasad K, Pearce C. Atherosclerosis and the hypercholesterolemic AGE-RAGE axis. Int. J. Angiol. 2016;25:110-116.
Not in our library10.1055/s-0035-1570754
121.
Prasad K, Dhar I, Caspar-Bell G. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int. J. Angiol. 2015;24:75-80.
Not in our library10.1055/s-0034-1396413
122.
Kiefer AS, et al. Methylglyoxal concentrations differ in standard and washed neonatal packed red blood cells. Pediatr. Res. 2014;75:409-414.
Not in our library10.1038/pr.2013.243
123.
Sousa Silva M, Gomes RA, Ferreira AE, Ponces Freire A, Cordeiro C. The glyoxalase pathway: the first hundred years… and beyond. Biochem. J. 2013;453:1-15.
Not in our library10.1042/bj20121743
124.
Koschinsky T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl Acad. Sci. USA. 1997;94:6474-6479.
Not in our library10.1073/pnas.94.12.6474
125.
Uribarri J, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet. Assoc. 2010;110:911-16.e12.
Not in our library10.1016/j.jada.2010.03.018
126.
Uribarri J, et al. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann. N. Y Acad. Sci. 2005;1043:461-466.
Not in our library10.1196/annals.1333.052
127.
Lin RY, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2003;168:213-220.
Not in our library10.1016/s0021-9150(03)00050-9
128.
Ramful D, et al. Citrus fruit extracts reduce advanced glycation end products (AGEs)- and H2O2-induced oxidative stress in human adipocytes. J. Agric Food Chem. 2010;58:11119-11129.
Not in our library10.1021/jf102762s
129.
Liu W, et al. Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging reactive carbonyl species. Food Funct. 2014;5:2996-3004.
Not in our library10.1039/c4fo00538d
130.
Schmidt AM, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl Acad. Sci. USA. 1994;91:8807-8811.
Not in our library10.1073/pnas.91.19.8807
131.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced Glycation End Products. Circulation. 2006;114:597-605.
Not in our library10.1161/circulationaha.106.621854
132.
Tam XH, et al. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin. Sci. 2011;120:81-89.
Not in our library10.1042/cs20100256
133.
McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am. J. Hypertens. 2007;20:242-247.
Not in our library10.1016/j.amjhyper.2006.08.009
134.
Gelžinský J, et al. Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population? Hypertens. Res. 2021;44:518-527.
Not in our library10.1038/s41440-020-00601-1
135.
Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study · 2021
Not checked
136.
Dimitriadis K, et al. Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 2013;23:382-388.
Not in our library10.1016/j.numecd.2011.10.003
137.
Geroldi D, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 2005;23:1725-1729.
Not in our library10.1097/01.hjh.0000177535.45785.64
138.
Colhoun HM, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011;60:2379-2385.
Not in our library10.2337/db11-0291
139.
Prasad K, Mishra M. Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension? Int. J. Angiol. 2017;26:1-11.
Not in our library10.1055/s-0037-1598183
140.
Schmidt AM, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 1995;96:1395-1403.
Not in our library10.1172/jci118175
141.
Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J. Mol. Biol. 1988;203:495-505.
Not in our library10.1016/0022-2836(88)90015-0
142.
Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol. Dial. Transpl. 1996;11:62-65.
Not in our library10.1093/ndt/11.supp5.62
143.
Reiser K, McCormick RJ, Rucker RB. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J. 1992;6:2439-2449.
Not in our library10.1096/fasebj.6.7.1348714
144.
Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann. N. Y Acad. Sci. 2011;1243:88-102.
Not in our library10.1111/j.1749-6632.2011.06320.x
145.
Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 2010;106:842-853.
Not in our library10.1161/circresaha.109.212217
146.
Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 1999;84:489-497.
Not in our library10.1161/01.res.84.5.489
147.
Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta. 2000;1498:99-111.
Not in our library10.1016/s0167-4889(00)00087-2
148.
Tóbon-Velasco JC, Cuevas E, Torres-Ramos MA. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS Neurol. Disord. Drug Targets. 2014;13:1615-1626.
Not in our library10.2174/1871527313666140806144831
149.
Wautier M-P, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001;280:E685-E694.
Not in our library10.1152/ajpendo.2001.280.5.e685
150.
Ott C, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411-429.
Not in our library10.1016/j.redox.2013.12.016
151.
Hofmann MA, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
Not in our library10.1016/s0092-8674(00)80801-6
152.
D’Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat. Rev. Nephrol. 2010;6:352-360.
Not in our library10.1038/nrneph.2010.54
153.
Farmer DG, Kennedy S. RAGE, vascular tone and vascular disease. Pharm. Ther. 2009;124:185-194.
Not in our library10.1016/j.pharmthera.2009.06.013
154.
Harja E, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J. Clin. Invest. 2008;118:183-194.
Not in our library10.1172/jci32703
155.
Hori O, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995;270:25752-25761.
Not in our library10.1074/jbc.270.43.25752
156.
Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med Chem. 2006;13:1971-1978.
Not in our library10.2174/092986706777585013
157.
Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial. 2007;20:103-109.
Not in our library10.1111/j.1525-139x.2007.00255.x
158.
Kalra SS, Shanahan CM. Vascular calcification and hypertension: cause and effect. Ann. Med. 2012;44:S85-92.
Not in our library10.3109/07853890.2012.660498
159.
Lanzer P, et al. Medial arterial calcification: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2021;78:1145-1165.
Not in our library10.1016/j.jacc.2021.06.049
160.
Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005;66:307-317.
Not in our library10.1016/j.cardiores.2005.01.012
161.
Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938-942.
Not in our library10.1161/hy1001.096358
162.
Niederhoffer N, et al. Calcification of medial elastic fibers and aortic elasticity. Hypertension. 1997;29:999-1006.
Not in our library10.1161/01.hyp.29.4.999
163.
Van den Bergh G, Opdebeeck B, D’Haese PC, Verhulst A. The vicious cycle of arterial stiffness and arterial media calcification. Trends Mol. Med. 2019;25:1133-1146.
Not in our library10.1016/j.molmed.2019.08.006
164.
Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz. 2001;26:245-251.
Not in our library10.1007/pl00002027
165.
Li N, et al. Vascular adventitia calcification and its underlying mechanism. PLoS ONE. 2015;10:e0132506.
Not in our library10.1371/journal.pone.0132506
166.
Hunt JL, et al. Bone formation in carotid plaques: a clinicopathological study. Stroke. 2002;33:1214-1219.
Not in our library10.1161/01.str.0000013741.41309.67
167.
Jeffcoate WJ, Rasmussen LM, Hofbauer LC, Game FL. Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia. 2009;52:2478-2488.
Not in our library10.1007/s00125-009-1521-6
168.
Villa-Bellosta R. New insights into endogenous mechanisms of protection against arterial calcification. Atherosclerosis. 2020;306:68-74.
Not in our library10.1016/j.atherosclerosis.2020.03.007
169.
Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75:890-897.
Not in our library10.1038/ki.2008.644
170.
Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia · 2019
No notice
171.
Ketteler M, Brandenburg V, Jahnen-Dechent W, Westenfeld R, Floege J. Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrol. Dial. Transpl. 2005;20:673-677.
Not in our library10.1093/ndt/gfh734
172.
Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ. Res. 2011;109:697-711.
Not in our library10.1161/circresaha.110.234914
173.
Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calcification in chronic kidney disease: an update. Nephrol. Dial. Transpl. 2016;31:31-39.
Not in our library10.1093/ndt/gfv111
174.
Lanzer P, et al. Medial vascular calcification revisited: review and perspectives. Eur. Heart J. 2014;35:1515-1525.
Not in our library10.1093/eurheartj/ehu163
175.
Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ. Res. 2006;99:1044-1059.
Not in our library10.1161/01.res.0000249379.55535.21
176.
Addison WN, Azari F, Sørensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J. Biol. Chem. 2007;282:15872-15883.
Not in our library10.1074/jbc.m701116200
177.
Moochhala SH. Extracellular pyrophosphate in the kidney: how does it get there and what does it do? Nephron Physiol. 2012;120:p33-8.
Not in our library10.1159/000341597
178.
Roberts F, Zhu D, Farquharson C, Macrae VE. ENPP1 in the regulation of mineralization and beyond. Trends Biochem. Sci. 2019;44:616-628.
Not in our library10.1016/j.tibs.2019.01.010
179.
Eytan O, et al. Cole disease results from mutations in ENPP1. Am. J. Hum. Genet. 2013;93:752-757.
Not in our library10.1016/j.ajhg.2013.08.007
180.
Chen IP, Luxmi R, Kanaujiya J, Hao Z, Reichenberger EJ. Craniometaphyseal dysplasia mutations in ANKH negatively affect human induced pluripotent stem cell differentiation into osteoclasts. Stem Cell Rep. 2017;9:1369-1376.
Not in our library10.1016/j.stemcr.2017.09.016
181.
Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000;289:265-270.
Not in our library10.1126/science.289.5477.265
182.
Williams CJ. The role of ANKH in pathologic mineralization of cartilage. Curr. Opin. Rheumatol. 2016;28:145-151.
Not in our library10.1097/bor.0000000000000247
183.
Paloian NJ, Giachelli CM. A current understanding of vascular calcification in CKD. Am. J. Physiol. Ren. Physiol. 2014;307:F891-900.
Not in our library10.1152/ajprenal.00163.2014
184.
Goettsch C, et al. Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J. Clin. Invest. 2016;126:1323-1336.
Not in our library10.1172/jci80851
185.
Roles and Regulation of Extracellular Vesicles in Cardiovascular Mineral Metabolism · 2018
Not checked
186.
Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117:2938-2948.
Not in our library10.1161/circulationaha.107.743161
187.
Kapustin AN, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ. Res. 2011;109:e1-12.
Not in our library10.1161/circresaha.110.238808
188.
Proudfoot D, et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ. Res. 2000;87:1055-1062.
Not in our library10.1161/01.res.87.11.1055
189.
Clarke MC, et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ. Res. 2008;102:1529-1538.
Not in our library10.1161/circresaha.108.175976
190.
Alesutan I, et al. Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine. Cardiovasc. Res. 2016;110:408-418.
Not in our library10.1093/cvr/cvw062
191.
Qiu C, et al. Vitamin K2 inhibits rat vascular smooth muscle cell calcification by restoring the Gas6/Axl/Akt anti-apoptotic pathway. Mol. Cell Biochem. 2017;433:149-159.
Not in our library10.1007/s11010-017-3023-z
192.
Son BK, et al. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur. J. Pharm. 2007;556:1-8.
Not in our library10.1016/j.ejphar.2006.09.070
193.
Son BK, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ. Res. 2006;98:1024-1031.
Not in our library10.1161/01.res.0000218859.90970.8d
194.
Lau WL, Festing MH, Giachelli CM. Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb. Haemost. 2010;104:464-470.
Not in our library10.1160/th09-12-0814
195.
Cui L, Bai Y, Zhang J, Zhang S, Xu J. Effects of extracellular acid stimulation on rat vascular smooth muscle cell in Gas6/Axl or PI3K/Akt signaling pathway. Clin. Exp. Hypertens. 2016;38:451-456.
Not in our library10.3109/10641963.2016.1163366
196.
Xu M, Liu L, Song C, Chen W, Gui S. Ghrelin improves vascular autophagy in rats with vascular calcification. Life Sci. 2017;179:23-29.
Not in our library10.1016/j.lfs.2016.11.025
197.
Son BK, et al. Adiponectin antagonizes stimulatory effect of tumor necrosis factor-alpha on vascular smooth muscle cell calcification: regulation of growth arrest-specific gene 6-mediated survival pathway by adenosine 5’-monophosphate-activated protein kinase. Endocrinology. 2008;149:1646-1653.
Not in our library10.1210/en.2007-1021
198.
Ma WQ, et al. Restoring mitochondrial biogenesis with metformin attenuates β-GP-induced phenotypic transformation of VSMCs into an osteogenic phenotype via inhibition of PDK4/oxidative stress-mediated apoptosis. Mol. Cell Endocrinol. 2019;479:39-53.
Not in our library10.1016/j.mce.2018.08.012
199.
Voelkl J, et al. Zinc inhibits phosphate-induced vascular calcification through TNFAIP3-mediated suppression of NF-κB. J. Am. Soc. Nephrol. 2018;29:1636-1648.
Not in our library10.1681/asn.2017050492
200.
Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells · 2017
Not checked
201.
Chen NX, Moe SM. Pathophysiology of vascular calcification. Curr. Osteoporos. Rep. 2015;13:372-380.
Not in our library10.1007/s11914-015-0293-9
202.
Voelkl J, et al. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J. Clin. Invest. 2013;123:812-822.
Not in our library10.1172/jci64093
203.
Leibrock CB, et al. NH4Cl treatment prevents tissue calcification in klotho deficiency. J. Am. Soc. Nephrol. 2015;26:2423-2433.
Not in our library10.1681/asn.2014030230
204.
Xu Z, et al. SOX9 and myocardin counteract each other in regulating vascular smooth muscle cell differentiation. Biochem. Biophys. Res.Commun. 2012;422:285-290.
Not in our library10.1016/j.bbrc.2012.04.149
205.
Alesutan I, et al. Inhibition of phosphate-induced vascular smooth muscle cell osteo-/chondrogenic signaling and calcification by bafilomycin A1 and methylamine. Kidney Blood Press Res. 2015;40:490-499.
Not in our library10.1159/000368524
206.
Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J. Cell Biochem. 2010;110:935-947.
Not in our library10.1002/jcb.22607
207.
Sun Y, et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ. Res. 2012;111:543-552.
Not in our library10.1161/circresaha.112.267237
208.
Lee HL, Woo KM, Ryoo HM, Baek JH. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem. Biophys. Res. Commun. 2010;391:1087-1092.
Not in our library10.1016/j.bbrc.2009.12.027
209.
Alencar GF, et al. Stem cell pluripotency genes Klf4 and Oct4 regulate complex SMC phenotypic changes critical in late-stage atherosclerotic lesion pathogenesis. Circulation. 2020;142:2045-2059.
Not in our library10.1161/circulationaha.120.046672
210.
Yoshida T, Yamashita M, Hayashi M. Kruppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. J. Biol. Chem. 2012;287:25706-25714.
Not in our library10.1074/jbc.m112.361360
211.
Zhu L, et al. Hyperhomocysteinemia induces vascular calcification by activating the transcription factor RUNX2 via Krüppel-like factor 4 up-regulation in mice. J. Biol. Chem. 2019;294:19465-19474.
Not in our library10.1074/jbc.ra119.009758
212.
Leibrock CB, et al. Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice. J. Mol. Med. 2016;94:95-106.
Not in our library10.1007/s00109-015-1331-x
213.
Shanahan CM, et al. Medial localization of mineralization-regulating proteins in association with Mönckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100:2168-2176.
Not in our library10.1161/01.cir.100.21.2168
214.
Forrester SJ, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol. Rev. 2018;98:1627-1738.
Not in our library10.1152/physrev.00038.2017
215.
Povlsen AL, Grimm D, Wehland M, Infanger M, Krüger M. The vasoactive mas receptor in essential hypertension. J. Clin. Med. 2020;9:267.
Not in our library10.3390/jcm9010267
216.
Santos RA, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl Acad. Sci. USA. 2003;100:8258-8263.
Not in our library10.1073/pnas.1432869100
217.
Santos RAS, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol. Rev. 2018;98:505-553.
Not in our library10.1152/physrev.00023.2016
218.
Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ. Res. 2015;116:960-975.
Not in our library10.1161/circresaha.116.303587
219.
Becher UM, Endtmann C, Tiyerili V, Nickenig G, Werner N. Endothelial damage and regeneration: the role of the renin-angiotensin-aldosterone system. Curr. Hypertens. Rep. 2011;13:86-92.
Not in our library10.1007/s11906-010-0171-x
220.
Li Y, Yan Z, Chaudhry K, Kazlauskas A. The renin-angiotensin-aldosterone system (RAAS) is one of the effectors by which vascular endothelial growth factor (VEGF)/anti-VEGF controls the endothelial cell barrier. Am. J. Pathol. 2020;190:1971-1981.
Not in our library10.1016/j.ajpath.2020.06.004
221.
Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-147.
Not in our library10.1016/s0008-6363(97)00097-7
222.
Ferrario CM, et al. Angiotensin (1-12) in humans with normal blood pressure and primary hypertension. Hypertension. 2021;77:882-890.
Not in our library10.1161/hypertensionaha.120.16514
223.
Azushima K, Morisawa N, Tamura K, Nishiyama A. Recent research advances in renin-angiotensin-aldosterone system receptors. Curr. Hypertens. Rep. 2020;22:22.
Not in our library10.1007/s11906-020-1028-6
224.
Balakumar P, et al. Unraveling the differentially articulated axes of the century-old renin-angiotensin-aldosterone system: potential therapeutic implications. Cardiovasc. Toxicol. 2022;22:246-253.
Not in our library10.1007/s12012-022-09724-y
225.
Basu S, et al. Notch transcriptional control of vascular smooth muscle regulatory gene expression and function. J. Biol. Chem. 2013;288:11191-11202.
Not in our library10.1074/jbc.m112.442996
226.
Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7). Exp. Physiol. 2008;93:528-537.
Not in our library10.1113/expphysiol.2007.040345
227.
Bader MACE2. angiotensin-(1–7), and Mas: the other side of the coin. Pflug. Arch. 2013;465:79-85.
Not in our library10.1007/s00424-012-1120-0
228.
From gene to proteinâ€”experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension · 2014
No notice
229.
Durand MJ, et al. Vascular actions of angiotensin 1-7 in the human microcirculation: novel role for telomerase. Arterioscler Thromb. Vasc. Biol. 2016;36:1254-1262.
Not in our library10.1161/atvbaha.116.307518
230.
Beyer AM, et al. Critical role for telomerase in the mechanism of flow-mediated dilation in the human microcirculation. Circ. Res. 2016;118:856-866.
Not in our library10.1161/circresaha.115.307918
231.
Ocaranza MP, et al. Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. J. Hypertens. 2011;29:706-715.
Not in our library10.1097/hjh.0b013e3283440665
232.
Siragy HM, Jaffa AA, Margolius HS. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. Hypertension. 1997;29:757-762.
Not in our library10.1161/01.hyp.29.3.757
233.
Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor–null mice. Hypertension. 2003;42:600-604.
Not in our library10.1161/01.hyp.0000090323.58122.5c
234.
Tsutsumi Y, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J. Clin. Invest. 1999;104:925-935.
Not in our library10.1172/jci7886
235.
Chai SY, et al. The angiotensin IV/AT4 receptor. Cell Mol. Life Sci. 2004;61:2728-2737.
Not in our library10.1007/s00018-004-4246-1
236.
Ichihara A, Yatabe MS. The (pro)renin receptor in health and disease. Nat. Rev. Nephrol. 2019;15:693-712.
Not in our library10.1038/s41581-019-0160-5
237.
Sakoda M, et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res. 2007;30:1139-1146.
Not in our library10.1291/hypres.30.1139
238.
Kurauchi-Mito A, et al. Significant roles of the (pro)renin receptor in integrity of vascular smooth muscle cells. Hypertens. Res. 2014;37:830-835.
Not in our library10.1038/hr.2014.92
239.
Krop M, Lu X, Danser AH, Meima ME. The (pro)renin receptor. A decade of research: what have we learned? Pflug. Arch. 2013;465:87-97.
Not in our library10.1007/s00424-012-1105-z
240.
Cruciat CM, et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science. 2010;327:459-463.
Not in our library10.1126/science.1179802
241.
Sihn G, Rousselle A, Vilianovitch L, Burckle C, Bader M. Physiology of the (pro)renin receptor: Wnt of change? Kidney Int. 2010;78:246-256.
Not in our library10.1038/ki.2010.151
242.
Parving HH, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 2012;367:2204-2213.
Not in our library10.1056/nejmoa1208799
243.
McCurley A, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat. Med. 2012;18:1429-1433.
Not in our library10.1038/nm.2891
244.
Koenig JB, Jaffe IZ. Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications. Curr. Hypertens. Rep. 2014;16:427.
Not in our library10.1007/s11906-014-0427-y
245.
Freinbichler W, et al. Highly reactive oxygen species: detection, formation, and possible functions. Cell Mol. Life Sci. 2011;68:2067-2079.
Not in our library10.1007/s00018-011-0682-x
246.
Wu R, et al. Redox signaling, mitochondrial metabolism, epigenetics and redox active phytochemicals. Free Radic. Biol. Med. 2022;179:328-336.
Not in our library10.1016/j.freeradbiomed.2020.12.007
247.
Forman HJ, Ursini F, Maiorino M. An overview of mechanisms of redox signaling. J. Mol. Cell Cardiol. 2014;73:2-9.
Not in our library10.1016/j.yjmcc.2014.01.018
248.
ROS and ROS‐Mediated Cellular Signaling · 2016
No notice
249.
Griendling KK, et al. Oxidative stress and hypertension. Circ. Res. 2021;128:993-1020.
Not in our library10.1161/circresaha.121.318063
250.
Majzunova M, Dovinova I, Barancik M, Chan JY. Redox signaling in pathophysiology of hypertension. J. Biomed. Sci. 2013;20:69.
Not in our library10.1186/1423-0127-20-69
251.
Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid. Redox Signal. 2008;10:1045-1059.
Not in our library10.1089/ars.2007.1986
252.
Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens. Res. 2011;34:5-14.
Not in our library10.1038/hr.2010.201
253.
Kemble DJ, Sun G. Direct and specific inactivation of protein tyrosine kinases in the Src and FGFR families by reversible cysteine oxidation. Proc. Natl Acad. Sci. USA. 2009;106:5070-5075.
Not in our library10.1073/pnas.0806117106
254.
Paulsen CE, Carroll KS. Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem. Biol. 2010;5:47-62.
Not in our library10.1021/cb900258z
255.
Burgoyne JR, et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science. 2007;317:1393-1397.
Not in our library10.1126/science.1144318
256.
Lyle AN, Griendling KK. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology. 2006;21:269-280.
Not in our library10.1152/physiol.00004.2006
257.
García-Redondo AB, et al. c-Src, ERK1/2 and Rho kinase mediate hydrogen peroxide-induced vascular contraction in hypertension: role of TXA2, NAD(P)H oxidase and mitochondria. J. Hypertens. 2015;33:77-87.
Not in our library10.1097/hjh.0000000000000383
258.
Liu Q, et al. The association between oxidative stress, activator protein-1, inflammatory, total antioxidant status and artery stiffness and the efficacy of olmesartan in elderly patients with mild-to-moderate essential hypertension. Clin. Exp. Hypertens. 2016;38:365-369.
Not in our library10.3109/10641963.2015.1131285
259.
Ferroni P, Basili S, Paoletti V, Davì G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr. Metab. Cardiovasc. Dis. 2006;16:222-233.
Not in our library10.1016/j.numecd.2005.11.012
260.
Gang C, et al. Puerarin suppresses angiotensin II-induced cardiac hypertrophy by inhibiting NADPH oxidase activation and oxidative stress-triggered AP-1 signaling pathways. J. Pharm. Pharm. Sci. 2015;18:235-248.
Not in our library10.18433/j3n318
261.
Chen B, Lu Y, Chen Y, Cheng J. The role of Nrf2 in oxidative stress-induced endothelial injuries. J. Endocrinol. 2015;225:R83-99.
Not in our library10.1530/joe-14-0662
262.
Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 2000;279:L1005-28.
Not in our library10.1152/ajplung.2000.279.6.l1005
263.
Bou-Teen D, et al. Mitochondrial ROS and mitochondria-targeted antioxidants in the aged heart. Free Radic. Biol. Med. 2021;167:109-124.
Not in our library10.1016/j.freeradbiomed.2021.02.043
264.
Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 2014;94:909-950.
Not in our library10.1152/physrev.00026.2013
265.
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential · 2020
No notice
266.
Schmidt HH, et al. Antioxidants in translational medicine. Antioxid. Redox Signal. 2015;23:1130-1143.
Not in our library10.1089/ars.2015.6393
267.
Schönfeld P, Dymkowska D, Wojtczak L. Acyl-CoA-induced generation of reactive oxygen species in mitochondrial preparations is due to the presence of peroxisomes. Free Radic. Biol. Med. 2009;47:503-509.
Not in our library10.1016/j.freeradbiomed.2009.05.006
268.
Liu Q, et al. A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. Proc. Natl Acad. Sci. USA. 2004;101:4302-4307.
Not in our library10.1073/pnas.0400265101
269.
Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062-1065.
Not in our library10.1126/science.1219855
270.
van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. Cold Spring Harb. Perspect. Biol. 2013;5:a011072.
Not in our library10.1101/cshperspect.a011072
271.
Aon MA, Cortassa S, O’Rourke B. Percolation and criticality in a mitochondrial network. Proc. Natl Acad. Sci. USA. 2004;101:4447-4452.
Not in our library10.1073/pnas.0307156101
272.
Zhang Y, Murugesan P, Huang K, Cai H. NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nat. Rev. Cardiol. 2020;17:170-194.
Not in our library10.1038/s41569-019-0260-8
273.
Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb. Vasc. Biol. 2004;24:677-683.
Not in our library10.1161/01.atv.0000112024.13727.2c
274.
El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp. Mol. Med. 2009;41:217-225.
Not in our library10.3858/emm.2009.41.4.058
275.
Fukui T, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ. Res. 1997;80:45-51.
Not in our library10.1161/01.res.80.1.45
276.
Zalba G, et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension. 2000;35:1055-1061.
Not in our library10.1161/01.hyp.35.5.1055
277.
Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107-1111.
Not in our library10.1161/hy1101.093423
278.
Landmesser U, Harrison DG. Oxidative stress and vascular damage in hypertension. Coron. Artery Dis. 2001;12:455-461.
Not in our library10.1097/00019501-200109000-00004
279.
Rajagopalan S, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Inves.t. 1996;97:1916-1923.
Not in our library10.1172/jci118623
280.
Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system—an endocrine and paracrine system. Endocrinology. 2003;144:2179-2183.
Not in our library10.1210/en.2003-0150
281.
Soe NN, et al. Cyclophilin A is required for angiotensin II-induced p47phox translocation to caveolae in vascular smooth muscle cells. Arterioscler Thromb. Vasc. Biol. 2013;33:2147-2153.
Not in our library10.1161/atvbaha.113.301894
282.
Basset O, et al. NADPH oxidase 1 deficiency alters caveolin phosphorylation and angiotensin II-receptor localization in vascular smooth muscle. Antioxid. Redox Signal. 2009;11:2371-2384.
Not in our library10.1089/ars.2009.2584
283.
Niethammer P, Grabher C, Look AT, Mitchison TJ. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature. 2009;459:996-999.
Not in our library10.1038/nature08119
284.
Colavitti R, et al. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J. Biol. Chem. 2002;277:3101-3108.
Not in our library10.1074/jbc.m107711200
285.
Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
Not in our library10.1126/science.270.5234.296
286.
Ren J, Bi Y, Sowers JR, Hetz C, Zhang Y. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat. Rev. Cardiol. 2021;18:499-521.
Not in our library10.1038/s41569-021-00511-w
287.
Young CN. Endoplasmic reticulum stress in the pathogenesis of hypertension. Exp. Physiol. 2017;102:869-884.
Not in our library10.1113/ep086274
288.
Cunard R. Endoplasmic reticulum stress, a driver or an innocent bystander in endothelial dysfunction associated with hypertension? Curr. Hypertens. Rep. 2017;19:64.
Not in our library10.1007/s11906-017-0762-x
289.
Ochoa CD, Wu RF, Terada LS. ROS signaling and ER stress in cardiovascular disease. Mol. Asp. Med. 2018;63:18-29.
Not in our library10.1016/j.mam.2018.03.002
290.
Szasz T, Thakali K, Fink GD, Watts SW. A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp. Biol. Med (Maywood). 2007;232:27-37.
Not in our library
291.
Ali SS, Ahsan H, Zia MK, Siddiqui T, Khan FH. Understanding oxidants and antioxidants: classical team with new players. J. Food Biochem. 2020;44:e13145.
Not in our library10.1111/jfbc.13145
292.
Role of Selenoproteins in Redox Regulation of Signaling and the Antioxidant System: A Review · 2020
No notice
293.
Ahmad KA, et al. Antioxidant therapy for management of oxidative stress induced hypertension. Free Radic. Res. 2017;51:428-438.
Not in our library10.1080/10715762.2017.1322205
294.
Redón J, et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension. 2003;41:1096-1101.
Not in our library10.1161/01.hyp.0000068370.21009.38
295.
Sáez GT, et al. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am. J. Hypertens. 2004;17:809-816.
Not in our library10.1016/j.amjhyper.2004.05.022
296.
Zhou L, et al. Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. Free Radic. Biol. Med. 2006;41:1384-1391.
Not in our library10.1016/j.freeradbiomed.2006.07.019
297.
Zhou XJ, Vaziri ND, Wang XQ, Silva FG, Laszik Z. Nitric oxide synthase expression in hypertension induced by inhibition of glutathione synthase. J. Pharm. Exp. Ther. 2002;300:762-767.
Not in our library10.1124/jpet.300.3.762
298.
Welch WJ, et al. Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response. Hypertension. 2006;48:934-941.
Not in our library10.1161/01.hyp.0000242928.57344.92
299.
Rodriguez-Iturbe B, et al. Association of mitochondrial SOD deficiency with salt-sensitive hypertension and accelerated renal senescence. J. Appl Physiol. 2007;102:255-260.
Not in our library10.1152/japplphysiol.00513.2006
300.
Role of Catalase in Oxidative Stress- and Age-Associated Degenerative Diseases · 2019
No notice
301.
Iqbal H, et al. Anti-inflammatory, anti-oxidant and cardio-protective properties of novel fluorophenyl benzimidazole in L-NAME-induced hypertensive rats. Eur. J. Pharm. 2022;929:175132.
Not in our library10.1016/j.ejphar.2022.175132
302.
Zhang J, et al. Neohesperidin protects angiotensin II-induced hypertension and vascular remodeling. Front Pharm. 2022;13:890202.
Not in our library10.3389/fphar.2022.890202
303.
Batista GMS, et al. Ascorbic acid inhibits vascular remodeling induced by mental stress in overweight/obese men. Life Sci. 2020;250:117554.
Not in our library10.1016/j.lfs.2020.117554
304.
Caillon A, Schiffrin EL. Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence. Curr. Hypertens. Rep. 2016;18:21.
Not in our library10.1007/s11906-016-0628-7
305.
Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the immune system in hypertension. Physiol. Rev. 2017;97:1127-1164.
Not in our library10.1152/physrev.00031.2016
306.
Caillon A, Paradis P, Schiffrin EL. Role of immune cells in hypertension. Br. J. Pharm. 2019;176:1818-1828.
Not in our library10.1111/bph.14427
307.
Tellides G, Pober JS. Inflammatory and immune responses in the arterial media. Circ. Res. 2015;116:312-322.
Not in our library10.1161/circresaha.116.301312
308.
Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications · 2018
No notice
309.
Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 2017;377:111-121.
Not in our library10.1056/nejmoa1701719
310.
Kanashiro A, et al. The role of neutrophils in neuro-immune modulation. Pharm. Res. 2020;151:104580.
Not in our library10.1016/j.phrs.2019.104580
311.
Vida G, et al. 2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. Faseb j. 2011;25:4476-4485.
Not in our library10.1096/fj.11-191007
312.
Abais-Battad JM, Dasinger JH, Fehrenbach DJ, Mattson DL. Novel adaptive and innate immunity targets in hypertension. Pharm. Res. 2017;120:109-115.
Not in our library10.1016/j.phrs.2017.03.015
313.
Xiao L, Harrison DG. Inflammation in hypertension. Can. J. Cardiol. 2020;36:635-647.
Not in our library10.1016/j.cjca.2020.01.013
314.
Zhang RM, McNerney KP, Riek AE, Bernal-Mizrachi C. Immunity and hypertension. Acta Physiol. 2021;231:e13487.
Not in our library10.1111/apha.13487
315.
Grüneboom A, et al. Imaging innate immunity. Immunol. Rev. 2022;306:293-303.
Not in our library10.1111/imr.13048
316.
O’Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors—redefining innate immunity. Nat. Rev. Immunol. 2013;13:453-460.
Not in our library10.1038/nri3446
317.
Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 2009;388:621-625.
Not in our library10.1016/j.bbrc.2009.08.062
318.
Vijay K. Toll-like receptors in immunity and inflammatory diseases: past, present, and future. Int. Immunopharmacol. 2018;59:391-412.
Not in our library10.1016/j.intimp.2018.03.002
319.
Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009;21:317-337.
Not in our library10.1093/intimm/dxp017
320.
De Batista PR, et al. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS ONE. 2014;9:e104020.
Not in our library10.1371/journal.pone.0104020
321.
Eissler R, et al. Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens. Res. 2011;34:551-558.
Not in our library10.1038/hr.2010.270
322.
Marketou ME, et al. TLR2 and TLR4 gene expression in peripheral monocytes in nondiabetic hypertensive patients: the effect of intensive blood pressure-lowering. J. Clin. Hypertens. 2012;14:330-335.
Not in our library10.1111/j.1751-7176.2012.00620.x
323.
Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats · 2012
Expression of concern
324.
Bomfim GF, et al. Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sci. 2015;122:1-7.
Not in our library10.1016/j.lfs.2014.12.001
325.
Lee GL, et al. TLR4-activated MAPK-IL-6 axis regulates vascular smooth muscle cell function. Int. J. Mol. Sci. 2016;17:1394.
Not in our library10.3390/ijms17091394
326.
Song Y, et al. TLR4/NF-κB/Ceramide signaling contributes to Ox-LDL-induced calcification of human vascular smooth muscle cells. Eur. J. Pharm. 2017;794:45-51.
Not in our library10.1016/j.ejphar.2016.11.029
327.
Carrillo-Sepulveda MA, Spitler K, Pandey D, Berkowitz DE, Matsumoto T. Inhibition of TLR4 attenuates vascular dysfunction and oxidative stress in diabetic rats. J. Mol. Med (Berl.). 2015;93:1341-1354.
Not in our library10.1007/s00109-015-1318-7
328.
McCarthy CG, et al. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc. Res. 2015;107:119-130.
Not in our library10.1093/cvr/cvv137
329.
Rodrigues FL, et al. Toll-like receptor 9 plays a key role in the autonomic cardiac and baroreflex control of arterial pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2015;308:R714-23.
Not in our library10.1152/ajpregu.00150.2014
330.
Takahashi M. NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc Res. 2022;118:372-385.
Not in our library10.1093/cvr/cvab010
331.
Toldo S, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharm. Ther. 2022;236:108053.
Not in our library10.1016/j.pharmthera.2021.108053
332.
Tai GJ, et al. NLRP3 inflammasome links vascular senescence to diabetic vascular lesions. Pharm. Res. 2022;178:106143.
Not in our library10.1016/j.phrs.2022.106143
333.
NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension · 2017
No notice
334.
Zhang X, et al. NLRP3 inflammasome is involved in calcium-sensing receptor-induced aortic remodeling in SHRs. Mediators Inflamm. 2019;2019:6847087.
Not in our library10.1155/2019/6847087
335.
Guzik TJ, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007;204:2449-2460.
Not in our library10.1084/jem.20070657
336.
Mattson DL, et al. Genetic mutation of recombination activating gene 1 in Dahl salt-sensitive rats attenuates hypertension and renal damage. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013;304:R407-14.
Not in our library10.1152/ajpregu.00304.2012
337.
Rudemiller N, Lund H, Jacob HJ, Geurts AM, Mattson DL. CD247 modulates blood pressure by altering T-lymphocyte infiltration in the kidney. Hypertension. 2014;63:559-564.
Not in our library10.1161/hypertensionaha.113.02191
338.
Korshunov VA, Daul M, Massett MP, Berk BC. Axl mediates vascular remodeling induced by deoxycorticosterone acetate-salt hypertension. Hypertension. 2007;50:1057-1062.
Not in our library10.1161/hypertensionaha.107.096289
339.
Batchu N, et al. Role of Axl in T-lymphocyte survival in salt-dependent hypertension. Arterioscler Thromb. Vasc. Biol. 2016;36:1638-1646.
Not in our library10.1161/atvbaha.116.307848
340.
Trott DW, et al. Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertension. 2014;64:1108-1115.
Not in our library10.1161/hypertensionaha.114.04147
341.
Chan CT, et al. Obligatory role for B cells in the development of angiotensin II-dependent hypertension. Hypertension. 2015;66:1023-1033.
Not in our library10.1161/hypertensionaha.115.05779
342.
Crowley SD, et al. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010;298:R1089-R1097.
Not in our library10.1152/ajpregu.00373.2009
343.
Sundgren NC, et al. IgG receptor FcγRIIB plays a key role in obesity-induced hypertension. Hypertension. 2015;65:456-462.
Not in our library10.1161/hypertensionaha.114.04670
344.
Madhur MS, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-507.
Not in our library10.1161/hypertensionaha.109.145094
345.
Benson LN, et al. The IFNγ-PDL1 pathway enhances CD8T-DCT interaction to promote hypertension. Circ. Res. 2022;130:1550-1564.
Not in our library10.1161/circresaha.121.320373
346.
Majeed B, et al. Interleukin-2/anti-interleukin-2 immune complex expands regulatory T cells and reduces angiotensin II-induced aortic stiffening. Int. J. Hypertens. 2014;2014:126365.
Not in our library10.1155/2014/126365
347.
Lamb FS, Choi H, Miller MR, Stark RJ. TNFα and reactive oxygen signaling in vascular smooth muscle cells in hypertension and atherosclerosis. Am. J. Hypertens. 2020;33:902-913.
Not in our library10.1093/ajh/hpaa089
348.
Asadikaram G, et al. The study of the serum level of IL-4, TGF-β, IFN-γ, and IL-6 in overweight patients with and without diabetes mellitus and hypertension. J. Cell Biochem. 2019;120:4147-4157.
Not in our library10.1002/jcb.27700
349.
Dale BL, et al. Critical role of Interleukin 21 and T follicular helper cells in hypertension and vascular dysfunction. JCI Insight. 2019;5:e129278.
Not in our library10.1172/jci.insight.129278
350.
Ye J, et al. Interleukin 22 promotes blood pressure elevation and endothelial dysfunction in angiotensin II–treated mice. J. Am. Heart Assoc. 2017;6:e005875.
Not in our library10.1161/jaha.117.005875
351.
Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Disco. 2019;18:749-769.
Not in our library10.1038/s41573-019-0041-4
352.
Raffin C, Vo LT, Bluestone JA. T(reg) cell-based therapies: challenges and perspectives. Nat. Rev. Immunol. 2020;20:158-172.
Not in our library10.1038/s41577-019-0232-6
353.
Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat. Rev. Immunol. 2020;20:55-70.
Not in our library10.1038/s41577-019-0203-y
354.
Meng X, et al. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 2016;13:167-179.
Not in our library10.1038/nrcardio.2015.169
355.
Cui C, et al. CD4(+) T-cell endogenous cystathionine γ lyase-hydrogen sulfide attenuates hypertension by sulfhydrating liver kinase B1 to promote T regulatory cell differentiation and proliferation. Circulation. 2020;142:1752-1769.
Not in our library10.1161/circulationaha.119.045344
356.
Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am. J. Physiol. Heart Circ. Physiol. 2010;298:H938-44.
Not in our library10.1152/ajpheart.00707.2009
357.
Kasal DA, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59:324-330.
Not in our library10.1161/hypertensionaha.111.181123
358.
Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb. Vasc. Biol. 2011;31:2534-2542.
Not in our library10.1161/atvbaha.111.233262
359.
Barhoumi T, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469-476.
Not in our library10.1161/hypertensionaha.110.162941
360.
Belanger KM, et al. Greater T regulatory cells in females attenuate DOCA-salt-induced increases in blood pressure versus males. Hypertension. 2020;75:1615-1623.
Not in our library10.1161/hypertensionaha.119.14089
361.
Vongpatanasin W, et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115:1020-1028.
Not in our library10.1161/circulationaha.106.664854
362.
Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ. Res. 2016;118:145-156.
Not in our library10.1161/circresaha.115.306656
363.
Campese VM, Ye S, Zhong H. Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2002;39:519-524.
Not in our library10.1161/hy0202.102815
364.
Rothman AM, et al. Effects of interleukin-1β inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS. Hypertension. 2020;75:477-482.
Not in our library10.1161/hypertensionaha.119.13642
365.
Scott-Solomon E, Boehm E, Kuruvilla R. The sympathetic nervous system in development and disease. Nat. Rev. Neurosci. 2021;22:685-702.
Not in our library10.1038/s41583-021-00523-y
366.
Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol. Rev. 2010;90:513-557.
Not in our library10.1152/physrev.00007.2009
367.
Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ. Res. 2015;116:976-990.
Not in our library10.1161/circresaha.116.303604
368.
Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur. Heart J. 2012;33:1058-1066.
Not in our library10.1093/eurheartj/ehs041
369.
Grassi G, et al. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J. Hypertens. 2000;18:587-593.
Not in our library10.1097/00004872-200018050-00012
370.
Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72.
Not in our library10.1161/01.hyp.31.1.68
371.
Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Sympathetic neural mechanisms in white-coat hypertension. J. Am. Coll. Cardiol. 2002;40:126-132.
Not in our library10.1016/s0735-1097(02)01931-9
372.
Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J. Am. Coll. Cardiol. 2001;38:1711-1717.
Not in our library10.1016/s0735-1097(01)01600-x
373.
Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension. 1998;31:64-67.
Not in our library10.1161/01.hyp.31.1.64
374.
Schlaich MP, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension. 2004;43:169-175.
Not in our library10.1161/01.hyp.0000103160.35395.9e
375.
Greenwood JP, Stoker JB, Mary DA. Single-unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation. 1999;100:1305-1310.
Not in our library10.1161/01.cir.100.12.1305
376.
Miyajima E, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17:1057-1062.
Not in our library10.1161/01.hyp.17.6.1057
377.
Johansson M, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation. 1999;99:2537-2542.
Not in our library10.1161/01.cir.99.19.2537
378.
Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE. Preeclampsia—a state of sympathetic overactivity. N. Engl. J. Med. 1996;335:1480-1485.
Not in our library10.1056/nejm199611143352002
379.
Nilsson H, Ljung B, Sjöblom N, Wallin BG. The influence of the sympathetic impulse pattern on contractile responses of rat mesenteric arteries and veins. Acta Physiol. Scand. 1985;123:303-309.
Not in our library10.1111/j.1748-1716.1985.tb07592.x
380.
Macefield VG, Wallin BG. Physiological and pathophysiological firing properties of single postganglionic sympathetic neurons in humans. J. Neurophysiol. 2018;119:944-956.
Not in our library10.1152/jn.00004.2017
381.
Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J. 1992;6:832-839.
Not in our library10.1096/fasebj.6.3.1346768
382.
Civantos Calzada B, Aleixandre de Artiñano A. Alpha-adrenoceptor subtypes. Pharm. Res. 2001;44:195-208.
Not in our library10.1006/phrs.2001.0857
383.
Docherty JR. Subtypes of functional alpha1-adrenoceptor. Cell Mol. Life Sci. 2010;67:405-417.
Not in our library10.1007/s00018-009-0174-4
384.
Sporkova A, Perez-Rivera A, Galligan JJ. Interaction between alpha(1)- and alpha(2)-adrenoreceptors contributes to enhanced constrictor effects of norepinephrine in mesenteric veins compared to arteries. Eur. J. Pharm. 2010;643:239-246.
Not in our library10.1016/j.ejphar.2010.06.021
385.
Stull JT, Gallagher PJ, Herring BP, Kamm KE. Vascular smooth muscle contractile elements. Cellular regulation. Hypertension. 1991;17:723-732.
Not in our library10.1161/01.hyp.17.6.723
386.
Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 2003;83:1325-1358.
Not in our library10.1152/physrev.00023.2003
387.
Aburto TK, Lajoie C, Morgan KG. Mechanisms of signal transduction during alpha 2-adrenergic receptor-mediated contraction of vascular smooth muscle. Circ. Res. 1993;72:778-785.
Not in our library10.1161/01.res.72.4.778
388.
Eelen G, Treps L, Li X, Carmeliet P. Basic and therapeutic aspects of angiogenesis updated. Circ. Res. 2020;127:310-329.
Not in our library10.1161/circresaha.120.316851
389.
NOTCH regulation of the endothelial cell phenotype · 2018
No notice
390.
Kiriakidis S, et al. Factor-inhibiting HIF-1 (FIH-1) is required for human vascular endothelial cell survival. FASEB J. 2015;29:2814-2827.
Not in our library10.1096/fj.14-252379
391.
Wilhelm K, et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature. 2016;529:216-220.
Not in our library10.1038/nature16498
392.
Control of endothelial quiescence by FOXO-regulated metabolites · 2021
No notice
393.
Alvandi Z, Bischoff J. Endothelial-mesenchymal transition in cardiovascular disease. Arterioscler Thromb. Vasc. Biol. 2021;41:2357-2369.
Not in our library10.1161/atvbaha.121.313788
394.
Kovacic JC, et al. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019;73:190-209.
Not in our library10.1016/j.jacc.2018.09.089
395.
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases · 2017
No notice
396.
Son M, Oh S, Jang JT, Son KH, Byun K. Pyrogallol-phloroglucinol-6 6-bieckol on attenuates high-fat diet-induced hypertension by modulating endothelial-to-mesenchymal transition in the aorta of mice. Oxid. Med. Cell Longev. 2021;2021:8869085.
Not in our library10.1155/2021/8869085
397.
Tang RN, et al. Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats. Int. J. Cardiol. 2013;162:92-99.
Not in our library10.1016/j.ijcard.2011.06.052
398.
Ma J, Liu T, Dong X. Advanced glycation end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase B signaling cascades. Mol. Vis. 2010;16:2669-2679.
Not in our library
399.
Sánchez-Duffhues G, et al. Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2. J. Pathol. 2019;247:333-346.
Not in our library10.1002/path.5193
400.
Zhang K, Kan H, Mao A, Geng L, Ma X. Single-cell analysis of salt-induced hypertensive mouse aortae reveals cellular heterogeneity and state changes. Exp. Mol. Med. 2021;53:1866-1876.
Not in our library10.1038/s12276-021-00704-w
401.
Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc. Res. 2012;95:156-164.
Not in our library10.1093/cvr/cvs115
402.
Chen PY, et al. Smooth muscle cell reprogramming in aortic aneurysms. Cell Stem Cell. 2020;26:542-557.e11.
Not in our library10.1016/j.stem.2020.02.013
403.
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ. Res. 2016;118:692-702.
Not in our library10.1161/circresaha.115.306361
404.
Pan H, et al. Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. Circulation. 2020;142:2060-2075.
Not in our library10.1161/circulationaha.120.048378
405.
Six Shades of Vascular Smooth Muscle Cells Illuminated by KLF4 (Krüppel-Like Factor 4) · 2021
No notice
406.
Wang W, et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ. Res. 2006;98:1032-1039.
Not in our library10.1161/01.res.0000218782.52610.dc
407.
Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc. Res. 2007;74:196-206.
Not in our library10.1016/j.cardiores.2007.02.008
408.
Wu J, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J. Clin. Invest. 2016;126:1607.
Not in our library10.1172/jci87425
409.
Hu HH, et al. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem. Biol. Interact. 2018;292:76-83.
Not in our library10.1016/j.cbi.2018.07.008
410.
Goumans MJ, Ten Dijke P. TGF-β signaling in control of cardiovascular function. Cold Spring Harb. Perspect. Biol. 2018;10:a022210.
Not in our library10.1101/cshperspect.a022210
411.
Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18:816-827.
Not in our library10.1096/fj.03-1273rev
412.
Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J. Invest. Dermatol. 2002;118:211-215.
Not in our library10.1046/j.1523-1747.2002.01641.x
413.
Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 2002;4:599-604.
Not in our library10.1038/ncb826
414.
Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr. Opin. Rheumatol. 2002;14:681-685.
Not in our library10.1097/00002281-200211000-00009
415.
Kaikita K, et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 2001;104:839-844.
Not in our library10.1161/hc3301.092803
416.
Samarakoon R, Higgins PJ. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb. Haemost. 2008;100:976-983.
Not in our library10.1160/th08-05-0273
417.
Li JH, et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 2004;18:176-178.
Not in our library10.1096/fj.02-1117fje
418.
O’Dowd BF, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136:355-360.
Not in our library10.1016/0378-1119(93)90495-o
419.
Tatemoto K, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 1998;251:471-476.
Not in our library10.1006/bbrc.1998.9489
420.
Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul. Pept. 2004;118:119-125.
Not in our library10.1016/j.regpep.2003.11.002
421.
Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul. Pept. 2005;126:233-240.
Not in our library10.1016/j.regpep.2004.10.019
422.
Pope GR, Roberts EM, Lolait SJ, O’Carroll AM. Central and peripheral apelin receptor distribution in the mouse: species differences with rat. Peptides. 2012;33:139-148.
Not in our library10.1016/j.peptides.2011.12.005
423.
Mughal A, Sun C, OʼRourke ST. Apelin reduces nitric oxide-induced relaxation of cerebral arteries by inhibiting activation of large-conductance, calcium-activated K channels. J. Cardiovasc. Pharm. 2018;71:223-232.
Not in our library10.1097/fjc.0000000000000563
424.
Tatemoto K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul. Pept. 2001;99:87-92.
Not in our library10.1016/s0167-0115(01)00236-1
425.
Japp AG, et al. Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 2008;52:908-913.
Not in our library10.1016/j.jacc.2008.06.013
426.
Jia YX, et al. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007;28:2023-2029.
Not in our library10.1016/j.peptides.2007.07.016
427.
Xie H, et al. Lowered circulating apelin is significantly associated with an increased risk for hypertension: A meta-analysis. Clin. Exp. Hypertens. 2017;39:435-440.
Not in our library10.1080/10641963.2016.1267199
428.
Mohammadi M, et al. Apelin as a candidate for hypertension management; a systematic review and meta-analysis on animal studies. Arch. Acad. Emerg. Med. 2022;10:e90.
Not in our library10.22037/aaem.v10i1.1704
429.
Siddiquee K, Hampton J, McAnally D, May L, Smith L. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br. J. Pharm. 2013;168:1104-1117.
Not in our library10.1111/j.1476-5381.2012.02192.x
430.
Sun X, et al. Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens. Res. 2011;34:701-706.
Not in our library10.1038/hr.2011.19
431.
Siddiquee K, et al. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J. Hypertens. 2011;29:724-731.
Not in our library10.1097/hjh.0b013e32834347de
432.
Sato T, et al. Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest. 2013;123:5203-5211.
Not in our library10.1172/jci69608
433.
Zhong JC, et al. Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2017;1863:1942-1950.
Not in our library10.1016/j.bbadis.2016.11.007
434.
Han X, Zhang DL, Yin DX, Zhang QD, Liu WH. Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA. Can. J. Physiol. Pharm. 2013;91:708-714.
Not in our library10.1139/cjpp-2013-0046
435.
Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54:598-604.
Not in our library10.1161/hypertensionaha.109.134619
436.
Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev. Cell. 2013;27:672-680.
Not in our library10.1016/j.devcel.2013.11.002
437.
Pauli A, et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science. 2014;343:1248636.
Not in our library10.1126/science.1248636
438.
Li Y, et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: A preliminary study. Clin. Exp. Hypertens. 2020;42:239-243.
Not in our library10.1080/10641963.2019.1619756
439.
Song J, Tang J, Zhang Z, Liu Y, Zhong J. Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension. Chin. Med. J. 2022;135:1019-1026.
Not in our library10.1097/cm9.0000000000001766
440.
Mughal A, O’Rourke ST. Vascular effects of apelin: mechanisms and therapeutic potential. Pharm. Ther. 2018;190:139-147.
Not in our library10.1016/j.pharmthera.2018.05.013
441.
Couvineau P, Llorens-Cortes C, Iturrioz X. Elabela/Toddler and apelin bind differently to the apelin receptor. Faseb j. 2020;34:7989-8000.
Not in our library10.1096/fj.201903029r
442.
Dong H, Jiang Y, Triggle CR, Li X, Lytton J. Novel role for K+-dependent Na+/Ca2+ exchangers in regulation of cytoplasmic free Ca2+ and contractility in arterial smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 2006;291:H1226-35.
Not in our library10.1152/ajpheart.00196.2006
443.
Cai X, Lytton J. Molecular cloning of a sixth member of the K+-dependent Na+/Ca2+ exchanger gene family, NCKX6. J. Biol. Chem. 2004;279:5867-5876.
Not in our library10.1074/jbc.m310908200
444.
Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiol. Rev. 1999;79:763-854.
Not in our library10.1152/physrev.1999.79.3.763
445.
Lytton J, Li XF, Dong H, Kraev A. K+-dependent Na+/Ca2+ exchangers in the brain. Ann. N. Y Acad. Sci. 2002;976:382-393.
Not in our library10.1111/j.1749-6632.2002.tb04765.x
446.
Iwamoto T, et al. Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle. Nat. Med. 2004;10:1193-1199.
Not in our library10.1038/nm1118
447.
Moore ED, et al. Coupling of the Na+/Ca2+ exchanger, Na+/K+ pump and sarcoplasmic reticulum in smooth muscle. Nature. 1993;365:657-660.
Not in our library10.1038/365657a0
448.
Jaitovich A, Bertorello AM. Salt, Na+,K+-ATPase and hypertension. Life Sci. 2010;86:73-78.
Not in our library10.1016/j.lfs.2009.10.019
449.
Hamlyn JM, et al. A circulating inhibitor of (Na+ + K+)ATPase associated with essential hypertension. Nature. 1982;300:650-652.
Not in our library10.1038/300650a0
450.
Dora KA, Gallagher NT, McNeish A, Garland CJ. Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ. Res. 2008;102:1247-1255.
Not in our library10.1161/circresaha.108.172379
451.
Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
Not in our library10.1038/24388
452.
Blaustein MP, et al. The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension. Hypertension. 2009;53:291-298.
Not in our library10.1161/hypertensionaha.108.119974
453.
Shen H, et al. The role of Na(+), K(+)-ATPase in the hypoxic vasoconstriction in isolated rat basilar artery. Vasc. Pharm. 2016;81:53-60.
Not in our library10.1016/j.vph.2016.02.004
454.
Matchkov VV, et al. Interaction between Na+/K+-pump and Na+/Ca2+-exchanger modulates intercellular communication. Circ. Res. 2007;100:1026-1035.
Not in our library10.1161/01.res.0000262659.09293.56
455.
Hangaard L, et al. Na-K-ATPase regulates intercellular communication in the vascular wall via cSrc kinase-dependent connexin43 phosphorylation. Am. J. Physiol. Cell Physiol. 2017;312:C385-C397.
Not in our library10.1152/ajpcell.00347.2016
456.
Pitzer AL, Van Beusecum JP, Kleyman TR, Kirabo A. ENaC in salt-sensitive hypertension: kidney and beyond. Curr. Hypertens. Rep. 2020;22:69.
Not in our library10.1007/s11906-020-01067-9
457.
Kusche-Vihrog K, Callies C, Fels J, Oberleithner H. The epithelial sodium channel (ENaC): Mediator of the aldosterone response in the vascular endothelium? Steroids. 2010;75:544-549.
Not in our library10.1016/j.steroids.2009.09.003
458.
Jia G, et al. Epithelial sodium channel in aldosterone-induced endothelium stiffness and aortic dysfunction. Hypertension. 2018;72:731-738.
Not in our library10.1161/hypertensionaha.118.11339
459.
Amiloride Improves Endothelial Function and Reduces Vascular Stiffness in Female Mice Fed a Western Diet · 2017
Not checked
460.
The endothelial αENaC contributes to vascular endothelial function in vivo. · 2017
Not checked
461.
Takahashi H, Yoshika M, Komiyama Y, Nishimura M. The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain. Hypertens. Res. 2011;34:1147-1160.
Not in our library10.1038/hr.2011.105
462.
Hoorn EJ, Gritter M, Cuevas CA, Fenton RA. Regulation of the renal NaCl cotransporter and its role in potassium homeostasis. Physiol. Rev. 2020;100:321-356.
Not in our library10.1152/physrev.00044.2018
463.
Pitzer A, et al. DC ENaC-dependent inflammasome activation contributes to salt-sensitive hypertension. Circ. Res. 2022;131:328-344.
Not in our library10.1161/circresaha.122.320818
464.
Dendritic Cell Amiloride-Sensitive Channels Mediate Sodium-Induced Inflammation and Hypertension · 2017
Not checked
465.
Liakos CI, et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am. J. Cardiovasc. Drugs. 2021;21:123-137.
Not in our library10.1007/s40256-020-00423-z
466.
Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J. Am. Heart Assoc. 2017;6:e004007.
Not in our library10.1161/jaha.116.004007
467.
Weber MA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211-220.
Not in our library10.1016/s2213-8587(15)00417-9
468.
Weber MA, et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2016;25:93-103.
Not in our library10.3109/08037051.2015.1116258
469.
List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.
Not in our library10.2337/dc08-1863
470.
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes · 2013
No notice
471.
Tikkanen I, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420-428.
Not in our library10.2337/dc14-1096
472.
Lovshin JA, Gilbert RE. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr. Hypertens. Rep. 2015;17:551.
Not in our library10.1007/s11906-015-0551-3
473.
Takeshige Y, et al. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens. Res. 2016;39:415-422.
Not in our library10.1038/hr.2016.2
474.
Cefalu WT, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183-1187.
Not in our library10.1007/s00125-015-3547-2
475.
DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 2017;13:11-26.
Not in our library10.1038/nrneph.2016.170
476.
Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2020;75:422-434.
Not in our library10.1016/j.jacc.2019.11.031
477.
Chilton R, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab. 2015;17:1180-1193.
Not in our library10.1111/dom.12572
478.
Striepe K, et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation. 2017;136:1167-1169.
Not in our library10.1161/circulationaha.117.029529
479.
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus · 2014
No notice
480.
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat · 2020
Not checked
481.
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity · 2014
No notice
482.
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart · 2019
No notice
483.
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity · 2018
Not checked
484.
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome · 2016
No notice
485.
Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol. Rev. 1994;74:323-364.
Not in our library10.1152/physrev.1994.74.2.323
486.
Guyenet PG. The sympathetic control of blood pressure. Nat. Rev. Neurosci. 2006;7:335-346.
Not in our library10.1038/nrn1902
487.
Hirooka Y. Sympathetic activation in hypertension: importance of the central nervous system. Am. J. Hypertens. 2020;33:914-926.
Not in our library10.1093/ajh/hpaa074
488.
Barman SM. 2019 Ludwig Lecture: rhythms in sympathetic nerve activity are a key to understanding neural control of the cardiovascular system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2020;318:R191-R205.
Not in our library10.1152/ajpregu.00298.2019
489.
Zubcevic J, et al. Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease. Hypertension. 2014;63:e129-39.
Not in our library10.1161/hypertensionaha.114.02440
490.
Zubcevic J, et al. Altered inflammatory response is associated with an impaired autonomic input to the bone marrow in the spontaneously hypertensive rat. Hypertension. 2014;63:542-550.
Not in our library10.1161/hypertensionaha.113.02722
491.
Jun JY, et al. Brain-mediated dysregulation of the bone marrow activity in angiotensin II-induced hypertension. Hypertension. 2012;60:1316-1323.
Not in our library10.1161/hypertensionaha.112.199547
492.
de Git KC, Adan RA. Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation. Obes. Rev. 2015;16:207-224.
Not in our library10.1111/obr.12243
493.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res. 2015;116:991-1006.
Not in our library10.1161/circresaha.116.305697
494.
Ataei Ataabadi E, et al. Nitric oxide-cGMP signaling in hypertension: current and future options for pharmacotherapy. Hypertension. 2020;76:1055-1068.
Not in our library10.1161/hypertensionaha.120.15856
495.
Wang A, et al. Statins attenuate cholesterol-induced ROS via inhibiting NOX2/NOX4 and mitochondrial pathway in collecting ducts of the kidney. BMC Nephrol. 2022;23:184.
Not in our library10.1186/s12882-022-02815-6
496.
Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. J. Atheroscler. Thromb. 2014;21:997-1010.
Not in our library10.5551/jat.24398
497.
Burger D, et al. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/ Rho kinase pathways targeted to lipid rafts. Arterioscler Thromb. Vasc. Biol. 2011;31:1898-1907.
Not in our library10.1161/atvbaha.110.222703
498.
Wu Y, Ding Y, Ramprasath T, Zou MH. Oxidative stress, GTPCH1, and endothelial nitric oxide synthase uncoupling in hypertension. Antioxid. Redox Signal. 2021;34:750-764.
Not in our library10.1089/ars.2020.8112
499.
Wallerath T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106:1652-1658.
Not in our library10.1161/01.cir.0000029925.18593.5c
500.
Xia N, Förstermann U, Li H. Effects of resveratrol on eNOS in the endothelium and the perivascular adipose tissue. Ann. N. Y Acad. Sci. 2017;1403:132-141.
Not in our library10.1111/nyas.13397
501.
Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res. 2007;75:303-314.
Not in our library10.1016/j.cardiores.2007.02.031
502.
Golshiri K, Ataei Ataabadi E, Portilla Fernandez EC, Jan Danser AH, Roks AJM. The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: focus on phosphodiesterase-1 and soluble guanylate cyclase. Basic Clin. Pharm. Toxicol. 2020;127:67-80.
Not in our library10.1111/bcpt.13319
503.
Samidurai A, et al. Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. Pharm. Ther. 2021;226:107858.
Not in our library10.1016/j.pharmthera.2021.107858
504.
Gilotra NA, et al. Acute hemodynamic effects and tolerability of phosphodiesterase-1 inhibition with ITI-214 in human systolic heart failure. Circ. Heart Fail. 2021;14:e008236.
Not in our library10.1161/circheartfailure.120.008236
505.
Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Disco. 2008;7:156-167.
Not in our library10.1038/nrd2466
506.
Corti R, Flammer AJ, Hollenberg NK, Lüscher TF. Cocoa and cardiovascular health. Circulation. 2009;119:1433-1441.
Not in our library10.1161/circulationaha.108.827022
507.
Ribeiro F, Alves AJ, Duarte JA, Oliveira J. Is exercise training an effective therapy targeting endothelial dysfunction and vascular wall inflammation? Int. J. Cardiol. 2010;141:214-221.
Not in our library10.1016/j.ijcard.2009.09.548
508.
Barton M. Prevention and endothelial therapy of coronary artery disease. Curr. Opin. Pharm. 2013;13:226-241.
Not in our library10.1016/j.coph.2013.05.005
509.
Esposito K, et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. J. Clin. Endocrinol. Metab. 2006;91:3676-3679.
Not in our library10.1210/jc.2006-0851
510.
Delgado GE, et al. Influence of smoking and smoking cessation on biomarkers of endothelial function and their association with mortality. Atherosclerosis. 2020;292:52-59.
Not in our library10.1016/j.atherosclerosis.2019.11.017
511.
Pepine CJ, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. Jama. 2003;290:2805-2816.
Not in our library10.1001/jama.290.21.2805
512.
Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of The American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2018;71:2199-2269.
Not in our library10.1016/j.jacc.2017.11.005
513.
Williams B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39:3021-3104.
Not in our library10.1093/eurheartj/ehy339
514.
Hansson L, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
Not in our library10.1016/s0140-6736(00)02526-5
515.
Schefe JH, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ. Res. 2006;99:1355-1366.
Not in our library10.1161/01.res.0000251700.00994.0d
516.
Sun Y, Danser AHJ, Lu X. (Pro)renin receptor as a therapeutic target for the treatment of cardiovascular diseases? Pharmacol. Res. 2017;125:48-56.
Not in our library10.1016/j.phrs.2017.05.016
517.
Nguyen G. Renin/prorenin receptors. Kidney Int. 2006;69:1503-1506.
Not in our library10.1038/sj.ki.5000265
518.
Ruilope LM, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266.
Not in our library10.1016/s0140-6736(09)61966-8
519.
Gu J, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharm. 2010;50:401-414.
Not in our library10.1177/0091270009343932
520.
Kario K, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698-705.
Not in our library10.1161/hypertensionaha.113.02002
521.
Supasyndh O, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (≥65 years) with systolic hypertension. Am. J. Hypertens. 2017;30:1163-1169.
Not in our library10.1093/ajh/hpx111
522.
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2022;24:4-131.
Not in our library10.1002/ejhf.2333
523.
Gheblawi M, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ. Res. 2020;126:1456-1474.
Not in our library10.1161/circresaha.120.317015
524.
Cunha TM, et al. The nonpeptide ANG-(1-7) mimic AVE 0991 attenuates cardiac remodeling and improves baroreflex sensitivity in renovascular hypertensive rats. Life Sci. 2013;92:266-275.
Not in our library10.1016/j.lfs.2012.12.008
525.
Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharm. Res. 2017;125:21-38.
Not in our library10.1016/j.phrs.2017.06.005
526.
Meng W, et al. Identification of a hydroxypyrimidinone compound (21) as a potent APJ receptor agonist for the potential treatment of heart failure. J. Med. Chem. 2021;64:18102-18113.
Not in our library10.1021/acs.jmedchem.1c01504
527.
Tissot AC, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371:821-827.
Not in our library10.1016/s0140-6736(08)60381-5
528.
Chen X, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension. 2013;61:408-416.
Not in our library10.1161/hypertensionaha.112.201020
529.
Brown MJ. Aliskiren. Circulation. 2008;118:773-784.
Not in our library10.1161/circulationaha.108.787630
530.
Alshahrani S. Aliskiren—a promising antioxidant agent beyond hypertension reduction. Chem. Biol. Interact. 2020;326:109145.
Not in our library10.1016/j.cbi.2020.109145
531.
Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 2015;11:242-252.
Not in our library10.1038/nrendo.2015.6
532.
Dingemanse J, Cavallaro M, Eydeler U. Single-dose pharmacokinetics of the renin inhibitor ACT-077825 in elderly and young subjects of both sexes. Pharmacology. 2014;94:135-142.
Not in our library10.1159/000362822
533.
Dingemanse J, Nicolas L. Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. Clin. Drug Investig. 2013;33:207-213.
Not in our library10.1007/s40261-013-0056-2
534.
Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-1091.
Not in our library10.1161/hypertensionaha.109.136655
535.
Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011;364:11-21.
Not in our library10.1056/nejmoa1009492
536.
Armanini D, Sabbadin C, Donà G, Clari G, Bordin L. Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Expert Opin. Pharmacother. 2014;15:909-912.
Not in our library10.1517/14656566.2014.896901
537.
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development · 2017
No notice
538.
Pitt B, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 2021;385:2252-2263.
Not in our library10.1056/nejmoa2110956
539.
Kolkhof P, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 2021;52:642-652.
Not in our library10.1159/000516213
540.
Fagart J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 2010;285:29932-29940.
Not in our library10.1074/jbc.m110.131342
541.
Meyers MJ, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J. Med. Chem. 2010;53:5979-6002.
Not in our library10.1021/jm100505n
542.
Nariai T, et al. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology. 2012;89:44-52.
Not in our library10.1159/000335559
543.
Pitt B, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 2013;34:2453-2463.
Not in our library10.1093/eurheartj/eht187
544.
Lenzini L, Zanotti G, Bonchio M, Rossi GP. Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data. Pharm. Res. 2021;163:105332.
Not in our library10.1016/j.phrs.2020.105332
545.
Robertson S, et al. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension. 2013;62:572-578.
Not in our library10.1161/hypertensionaha.113.01102
546.
Hopps E, Caimi G. Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur. Rev. Med. Pharm. Sci. 2015;19:2583-2589.
Not in our library
547.
Fontana V, et al. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. Cardiovasc. Drugs Ther. 2012;26:511-519.
Not in our library10.1007/s10557-012-6420-2
548.
Uzui H, et al. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. J. Cardiovasc. Pharm. Ther. 2014;19:304-309.
Not in our library10.1177/1074248413511692
549.
Ceron CS, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br. J. Pharm. 2010;160:77-87.
Not in our library10.1111/j.1476-5381.2010.00678.x
550.
Ercan E, et al. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Kardiol. Pol. 2004;60:454-458.
Not in our library
551.
Madsen EL, et al. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism. 2009;58:946-953.
Not in our library10.1016/j.metabol.2009.02.031
552.
Ress C, et al. Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levels. Eur. Cytokine Netw. 2010;21:65-70.
Not in our library10.1684/ecn.2009.0177
553.
Winchester L, Veeranki S, Givvimani S, Tyagi SC. Exercise mitigates the adverse effects of hyperhomocysteinemia on macrophages, MMP-9, skeletal muscle, and white adipocytes. Can. J. Physiol. Pharm. 2014;92:575-582.
Not in our library10.1139/cjpp-2014-0059
554.
Macaulay VM, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 1999;5:513-520.
Not in our library
555.
Acharya MR, Venitz J, Figg WD, Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat. 2004;7:195-208.
Not in our library10.1016/j.drup.2004.04.002
556.
Naglich JG, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 2001;61:8480-8485.
Not in our library
557.
Lutz J, et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation. 2005;79:655-661.
Not in our library10.1097/01.tp.0000151644.85832.b5
558.
Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat. Rev. Drug Disco. 2014;13:904-927.
Not in our library10.1038/nrd4390
559.
Deng R, et al. Glucose-derived AGEs promote migration and invasion of colorectal cancer by up-regulating Sp1 expression. Biochim. Biophys. Acta Gen. Subj. 2017;1861:1065-1074.
Not in our library10.1016/j.bbagen.2017.02.024
560.
Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232:1629-1632.
Not in our library10.1126/science.3487117
561.
Weng S, et al. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. PLoS One. 2013;8:e54625.
Not in our library10.1371/journal.pone.0054625
562.
Sebeková K, et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J. Hum. Hypertens. 2003;17:265-270.
Not in our library10.1038/sj.jhh.1001541
563.
Diamanti-Kandarakis E, et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism. 2007;56:129-134.
Not in our library10.1016/j.metabol.2006.09.006
564.
Ito H, et al. Ellagitannin oligomers and a neolignan from pomegranate arils and their inhibitory effects on the formation of advanced glycation end products. Food Chem. 2014;152:323-330.
Not in our library10.1016/j.foodchem.2013.11.160
565.
A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys · 2001
Not checked
566.
Toprak C, Yigitaslan S. Alagebrium and complications of diabetes mellitus. Eurasia. J. Med. 2019;51:285-292.
Not in our library10.5152/eurasianjmed.2019.18434
567.
Forbes JM, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53:1813-1823.
Not in our library10.2337/diabetes.53.7.1813
568.
Lanati N, Emanuele E, Brondino N, Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr. Vasc. Pharm. 2010;8:86-92.
Not in our library10.2174/157016110790226642
569.
Prasad K, Tiwari S. Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease. Curr. Pharm. Des. 2017;23:937-943.
Not in our library10.2174/1381612822666161006143032
570.
Villa-Bellosta R, et al. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation. 2013;127:2442-2451.
Not in our library10.1161/circulationaha.112.000571
571.
Pomozi V, et al. Pyrophosphate supplementation prevents chronic and acute calcification in ABCC6-deficient mice. Am. J. Pathol. 2017;187:1258-1272.
Not in our library10.1016/j.ajpath.2017.02.009
572.
de Oliveira RB, et al. Peritoneal delivery of sodium pyrophosphate blocks the progression of pre-existing vascular calcification in uremic apolipoprotein-E knockout mice. Calcif. Tissue Int. 2015;97:179-192.
Not in our library10.1007/s00223-015-0020-7
573.
Tani T, et al. Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. J. Pathol. 2020;250:30-41.
Not in our library10.1002/path.5346
574.
Ziegler SG, et al. Ectopic calcification in pseudoxanthoma elasticum responds to inhibition of tissue-nonspecific alkaline phosphatase. Sci. Transl. Med. 2017;9:eaal1669.
Not in our library10.1126/scitranslmed.aal1669
575.
Li Q, et al. Inhibition of tissue-nonspecific alkaline phosphatase attenuates ectopic mineralization in the Abcc6(-/-) mouse model of PXE but not in the Enpp1 mutant mouse models of GACI. J. Invest. Dermatol. 2019;139:360-368.
Not in our library10.1016/j.jid.2018.07.030
576.
ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy · 2015
No notice
577.
Ferrer MD, et al. A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma. Sci. Rep. 2017;7:6858.
Not in our library10.1038/s41598-017-07203-x
578.
Ferrer MD, et al. Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification. PLoS ONE. 2018;13:e0197061.
Not in our library10.1371/journal.pone.0197061
579.
Ma WQ, Sun XJ, Zhu Y, Liu NF. Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects. Free Radic. Biol. Med. 2021;165:229-242.
Not in our library10.1016/j.freeradbiomed.2021.01.033
580.
Phadwal K, Feng D, Zhu D, MacRae VE. Autophagy as a novel therapeutic target in vascular calcification. Pharm. Ther. 2020;206:107430.
Not in our library10.1016/j.pharmthera.2019.107430
581.
Dai XY, et al. Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release. Kidney Int. 2013;83:1042-1051.
Not in our library10.1038/ki.2012.482
582.
Frauscher B, et al. Autophagy protects from uremic vascular media calcification. Front. Immunol. 2018;9:1866.
Not in our library10.3389/fimmu.2018.01866
583.
Yang L, et al. Unspliced XBP1 counteracts β-catenin to inhibit vascular calcification. Circ. Res. 2022;130:213-229.
Not in our library10.1161/circresaha.121.319745
584.
Nakatani S, Mori K, Shoji T, Emoto M. Association of zinc deficiency with development of CVD events in patients with CKD. Nutrients. 2021;13:1680.
Not in our library10.3390/nu13051680
585.
Castrejón-Téllez V, et al. Effect of a resveratrol/quercetin mixture on the reversion of hypertension induced by a short-term exposure to high sucrose levels near weaning and a long-term exposure that leads to metabolic syndrome in rats. Int. J. Mol. Sci. 2020;21:2231.
Not in our library10.3390/ijms21062231
586.
Prysyazhna O, et al. Blood pressure-lowering by the antioxidant resveratrol is counterintuitively mediated by oxidation of cGMP-dependent protein kinase. Circulation. 2019;140:126-137.
Not in our library10.1161/circulationaha.118.037398
587.
Huang J, Weinstein SJ, Yu K, Männistö S, Albanes D. Relationship between serum alpha-tocopherol and overall and cause-specific mortality. Circ. Res. 2019;125:29-40.
Not in our library10.1161/circresaha.119.314944
588.
Li Z, Chen J, Zhang D. Association between dietary carotenoid intakes and hypertension in adults: National Health and Nutrition Examination Survey 2007-2014. J. Hypertens. 2019;37:2371-2379.
Not in our library10.1097/hjh.0000000000002200
589.
Ulker S, McKeown PP, Bayraktutan U. Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension. 2003;41:534-539.
Not in our library10.1161/01.hyp.0000057421.28533.37
590.
Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229.
Not in our library10.1161/01.cir.97.22.2222
591.
Duffy SJ, et al. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am. J. Physiol. Heart Circ. Physiol. 2001;280:H528-34.
Not in our library10.1152/ajpheart.2001.280.2.h528
592.
Rodrigo R, Gil D, Miranda-Merchak A, Kalantzidis G. Antihypertensive role of polyphenols. Adv. Clin. Chem. 2012;58:225-254.
Not in our library10.1016/b978-0-12-394383-5.00014-x
593.
Ward NC, et al. The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial. J. Hypertens. 2005;23:427-434.
Not in our library10.1097/00004872-200502000-00026
594.
Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol. 2020;21:363-383.
Not in our library10.1038/s41580-020-0230-3
595.
Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 2000;86:494-501.
Not in our library10.1161/01.res.86.5.494
596.
Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ. Res. 1992;70:1099-1103.
Not in our library10.1161/01.res.70.6.1099
597.
Matsubara M, Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis. 2005;178:57-66.
Not in our library10.1016/j.atherosclerosis.2004.08.020
598.
Cho HY, et al. Comparative effect of genistein and daidzein on the expression of MCP-1, eNOS, and cell adhesion molecules in TNF-α-stimulated HUVECs. Nutr. Res. Pr. 2011;5:381-388.
Not in our library10.4162/nrp.2011.5.5.381
599.
Barrios V, Calderón A, Navarro-Cid J, Lahera V, Ruilope LM. N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients. Blood Press. 2002;11:235-239.
Not in our library10.1080/08037050213760
600.
Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Jama. 2008;300:924-932.
Not in our library10.1001/jama.300.8.924
601.
Mazzali M, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106.
Not in our library10.1161/hy1101.092839
602.
Di Raimondo D, et al. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr. Pharm. Des. 2012;18:4385-4413.
Not in our library10.2174/138161212802481282
603.
Roles of Inflammation, Oxidative Stress, and Vascular Dysfunction in Hypertension · 2014
No notice
604.
Rodríguez-Iturbe B, et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am. J. Physiol. Ren. Physiol. 2002;282:F191-201.
Not in our library10.1152/ajprenal.0197.2001
605.
Tian N, et al. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am. J. Physiol. Heart Circ. Physiol. 2007;292:H1018-25.
Not in our library10.1152/ajpheart.00487.2006
606.
Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension. 2006;48:149-156.
Not in our library10.1161/01.hyp.0000228320.23697.29
607.
Mediterranean diet and endothelial function in patients with coronary heart disease: An analysis of the CORDIOPREV randomized controlled trial · 2020
No notice
608.
Di Francescomarino S, Sciartilli A, Di Valerio V, Di Baldassarre A, Gallina S. The effect of physical exercise on endothelial function. Sports Med. 2009;39:797-812.
Not in our library10.2165/11317750-000000000-00000
609.
MacIntyre IM, et al. Regular acetaminophen use and blood pressure in people with hypertension: the PATH-BP trial. Circulation. 2022;145:416-423.
Not in our library10.1161/circulationaha.121.056015
610.
Spence JD, Grosser T, FitzGerald GA. Acetaminophen, nonsteroidal anti-inflammatory drugs, and hypertension. Hypertension. 2022;79:1922-1926.
Not in our library10.1161/hypertensionaha.122.19315
611.
Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017;377:1119-1131.
Not in our library10.1056/nejmoa1707914
612.
Everett BM, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139:1289-1299.
Not in our library10.1161/circulationaha.118.038010
613.
Ridker PM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391:319-328.
Not in our library10.1016/s0140-6736(17)32814-3
614.
Ridker PM, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur. Heart J. 2018;39:3499-3507.
Not in our library10.1093/eurheartj/ehy310
615.
Dalekos GN, Elisaf MS, Papagalanis N, Tzallas C, Siamopoulos KC. Elevated interleukin-1 beta in the circulation of patients with essential hypertension before any drug therapy: a pilot study. Eur. J. Clin. Invest. 1996;26:936-939.
Not in our library10.1111/j.1365-2362.1996.tb02141.x
616.
Madhur MS, et al. Hypertension: do inflammation and immunity hold the key to solving this epidemic? Circ. Res. 2021;128:908-933.
Not in our library10.1161/circresaha.121.318052
617.
Zhang F, Steinberg SF. S49G and R389G polymorphisms of the β1-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways. Physiol. Genomics. 2013;45:1186-1192.
Not in our library10.1152/physiolgenomics.00087.2013
618.
Sorota S. The sympathetic nervous system as a target for the treatment of hypertension and cardiometabolic diseases. J. Cardiovasc Pharm. 2014;63:466-476.
Not in our library10.1097/fjc.0000000000000064
619.
Sica DA. Centrally acting antihypertensive agents: an update. J. Clin. Hypertens. 2007;9:399-405.
Not in our library10.1111/j.1524-6175.2007.07161.x
620.
Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs. 2006;66:477-496.
Not in our library10.2165/00003495-200666040-00006
621.
Morris ST, Reid JL. Moxonidine: a review. J. Hum. Hypertens. 1997;11:629-635.
Not in our library10.1038/sj.jhh.1000518
622.
Laurent S. Antihypertensive drugs. Pharm. Res. 2017;124:116-125.
Not in our library10.1016/j.phrs.2017.07.026
623.
Hashmonai M, Cameron AE, Licht PB, Hensman C, Schick CH. Thoracic sympathectomy: a review of current indications. Surg. Endosc. 2016;30:1255-1269.
Not in our library10.1007/s00464-015-4353-0
624.
Bhatt DL, et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014;370:1393-1401.
Not in our library10.1056/nejmoa1402670
625.
Azizi M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476-2486.
Not in our library10.1016/s0140-6736(21)00788-1
626.
Wallbach M, et al. Effects of baroreflex activation therapy on ambulatory blood pressure in patients with resistant hypertension. Hypertension. 2016;67:701-709.
Not in our library10.1161/hypertensionaha.115.06717
627.
Mancia G, et al. The sympathetic nervous system and the metabolic syndrome. J. Hypertens. 2007;25:909-920.
Not in our library10.1097/hjh.0b013e328048d004
628.
Straznicky NE, et al. Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes. 2010;59:71-79.
Not in our library10.2337/db09-0934
629.
Trombetta IC, et al. Weight loss improves neurovascular and muscle metaboreflex control in obesity. Am. J. Physiol. Heart Circ. Physiol. 2003;285:H974-82.
Not in our library10.1152/ajpheart.01090.2002
630.
Zucker IH, et al. Exercise training and sympathetic regulation in experimental heart failure. Exerc Sport Sci. Rev. 2004;32:107-111.
Not in our library10.1097/00003677-200407000-00006
631.
Lucini D, Di Fede G, Parati G, Pagani M. Impact of chronic psychosocial stress on autonomic cardiovascular regulation in otherwise healthy subjects. Hypertension. 2005;46:1201-1206.
Not in our library10.1161/01.hyp.0000185147.32385.4b
632.
Oneda B, Ortega KC, Gusmão JL, Araújo TG, Mion D. Sympathetic nerve activity is decreased during device-guided slow breathing. Hypertens. Res. 2010;33:708-712.
Not in our library10.1038/hr.2010.74
633.
Viskoper R, et al. Nonpharmacologic treatment of resistant hypertensives by device-guided slow breathing exercises. Am. J. Hypertens. 2003;16:484-487.
Not in our library10.1016/s0895-7061(03)00571-5
634.
Anderson DE, McNeely JD, Windham BG. Regular slow-breathing exercise effects on blood pressure and breathing patterns at rest. J. Hum. Hypertens. 2010;24:807-813.
Not in our library10.1038/jhh.2010.18
635.
Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113:2335-2362.
Not in our library10.1161/circulationaha.104.482570
636.
Sesso HD, et al. C-reactive protein and the risk of developing hypertension. Jama. 2003;290:2945-2951.
Not in our library10.1001/jama.290.22.2945
637.
Di Pietro P, et al. Targeting the ASMase/S1P pathway protects from sortilin-evoked vascular damage in hypertension. J. Clin. Invest. 2022;132:e146343.
Not in our library10.1172/jci146343
638.
Citterio L, et al. Klotho gene in human salt-sensitive hypertension. Clin. J. Am. Soc. Nephrol. 2020;15:375-383.
Not in our library10.2215/cjn.08620719
639.
Shimizu Y, et al. Platelets and circulating CD34-positive cells as an indicator of the activity of the vicious cycle between hypertension and endothelial dysfunction in elderly Japanese men. Atherosclerosis. 2017;259:26-31.
Not in our library10.1016/j.atherosclerosis.2017.02.016
640.
Pandey A, et al. Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC/AHA high blood pressure guideline: a pooled cohort analysis. Circulation. 2019;140:2076-2088.
Not in our library10.1161/circulationaha.119.043337
641.
Ibsen H, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202.
Not in our library10.1161/01.hyp.0000154082.72286.2a
642.
Goettsch C, Kjolby M, Aikawa E. Sortilin and its multiple roles in cardiovascular and metabolic diseases. Arterioscler Thromb. Vasc. Biol. 2018;38:19-25.
Not in our library10.1161/atvbaha.117.310292
643.
Jujic A, et al. Plasma S1P (sphingosine-1-phosphate) links to hypertension and biomarkers of inflammation and cardiovascular disease: findings from a translational investigation. Hypertension. 2021;78:195-209.
Not in our library10.1161/hypertensionaha.120.17379
644.
Drew DA, et al. Soluble Klotho and Incident Hypertension. Clin. J. Am. Soc. Nephrol. 2021;16:1502-1511.
Not in our library10.2215/cjn.05020421
645.
Zhang JR, Sun HJ. MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction. Hypertens. Res. 2021;44:129-146.
Not in our library10.1038/s41440-020-00553-6
646.
Jusic A, Devaux Y. Noncoding RNAs in hypertension. Hypertension. 2019;74:477-492.
Not in our library10.1161/hypertensionaha.119.13412
647.
Lazaridis A, et al. A study of endothelial and platelet microvesicles across different hypertension phenotypes. J. Hum. Hypertens. 2022;36:561-569.
Not in our library10.1038/s41371-021-00531-6
648.
Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of hypertension: the mosaic theory and beyond. Circ. Res. 2021;128:847-863.
Not in our library10.1161/circresaha.121.318082
649.
Unger T, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334-1357.
Not in our library10.1161/hypertensionaha.120.15026
650.
Cuspidi C, Tadic M, Grassi G, Mancia G. Treatment of hypertension: the ESH/ESC guidelines recommendations. Pharm. Res. 2018;128:315-321.
Not in our library10.1016/j.phrs.2017.10.003
651.
Wang Z, et al. Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. Circulation. 2018;137:2344-2356.
Not in our library10.1161/circulationaha.117.032380
652.
Lewis CE, et al. Final report of a trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 2021;384:1921-1930.
Not in our library10.1056/nejmoa1901281
653.
Zhang W, et al. Trial of intensive blood-pressure control in older patients with hypertension. N. Engl. J. Med. 2021;385:1268-1279.
Not in our library10.1056/nejmoa2111437
654.
Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30:160-164.
Not in our library10.1016/j.tcm.2019.05.003
655.
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis · 2021
Corrected
656.
Xiong T, et al. Single-cell sequencing analysis and multiple machine learning methods identified G0S2 and HPSE as novel biomarkers for abdominal aortic aneurysm. Front. Immunol. 2022;13:907309.
Not in our library10.3389/fimmu.2022.907309
657.
Bauer Y, et al. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. Eur. Respir. J. 2021;57:2002591.
Not in our library10.1183/13993003.02591-2020
658.
Sandner, P. et al. Soluble GC stimulators and activators: past, present and future. Br. J. Pharmacol.10.1111/bph.15698 (2021).
Not in our library10.1111/bph.15698
659.
Tocci G, et al. How to improve effectiveness and adherence to antihypertensive drug therapy: central role of dihydropyridinic calcium channel blockers in hypertension. High. Blood Press Cardiovasc. Prev. 2018;25:25-34.
Not in our library10.1007/s40292-017-0242-z
660.
Pitt B. Diversity of calcium antagonists. Clin. Ther. 1997;19:3-17.
Not in our library10.1016/s0149-2918(97)80033-1
661.
Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. Exp. Suppl. 2012;103:209-279.
Not in our library10.1007/978-3-0348-0364-9_7
662.
Pohl M, Sakurai H, Bush KT, Nigam SK. Matrix metalloproteinases and their inhibitors regulate in vitro ureteric bud branching morphogenesis. Am. J. Physiol. Ren. Physiol. 2000;279:F891-900.
Not in our library10.1152/ajprenal.2000.279.5.f891
663.
Honda H, et al. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients. Clin. Exp. Hypertens. 2012;34:17-23.
Not in our library10.3109/10641963.2011.628726
664.
Doggrell SA. ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure. Expert Opin. Investig. Drugs. 2001;10:981-983.
Not in our library10.1517/13543784.10.5.981
665.
Susic D, Varagic J, Ahn J, Frohlich ED. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats. Am. J. Hypertens. 2004;17:328-333.
Not in our library10.1016/j.amjhyper.2003.12.015
666.
Resveratrol and Its Effects on the Vascular System · 2019
No notice
667.
Barrios V, Escobar C, Calderon A, Lahera V. N-acetylcysteine for the prevention of atrial fibrillation: beyond its antioxidant effect. Eur. Heart J. 2008;29:2822-2823.
Not in our library10.1093/eurheartj/ehn445
668.
Desiniotis A, Kyprianou N. Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opin. Ther. Targets. 2011;15:1405-1418.
Not in our library10.1517/14728222.2011.641534
669.
Crassous PA, Denis C, Paris H, Sénard JM. Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives. Curr. Top. Med Chem. 2007;7:187-194.
Not in our library10.2174/156802607779318190

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.